https://betafinch.comenInvesting2026 Beta Finchhttps://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/127d9472570a2727df2fd39c2d79348b.jpghttps://betafinch.comFri, 31 Jul 2026 21:51:49 +0000Beta FinchBeta Finchcontact@betafinch.comLeading pharmaceutical and biotechnology companies. AI-powered earnings call analysis for Pharma & Biotech (PHARMA). Two AI hosts break down quarterly results, key metrics, and market implications in digestible podcast episodes.falsetrueepisodichttps://www.spreaker.com/episode/abbvie-q2-2026-earnings-analysis--73295026https://betafinch.com
Groups: PHARMA (https://betafinch.com/groups/PHARMA)
──────────
ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. Today we're digging into AbbVie's second quarter 2026 results, and this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

JORDAN: And Alex, this was another really strong quarter for AbbVie. Let's just get right into the numbers.

ALEX: Yeah, so adjusted EPS came in at $3.65, which beat guidance by six cents. Total revenue was nearly $17 billion, up 10.2% year over year, and that beat expectations by $300 million. On the back of that, they raised full-year revenue guidance to about $67.6 billion — that's the second raise this year, $600 million total.

JORDAN: What jumps out to me is the breadth of the growth. It's not just one drug carrying the load. SKYRIZI, RINVOQ, and the entire neuroscience portfolio all grew north of 20%. SKYRIZI alone did $5.5 billion in the quarter, up 24%. RINVOQ crossed $2.5 billion, up almost 24%.

ALEX: And that's the story that matters most for AbbVie long-term — how well they've replaced the HUMIRA revenue. Speaking of which, HUMIRA sales were down 36% due to biosimilar competition, but that's expected and honestly just noise at this point given how much SKYRIZI and RINVOQ have scaled up.

JORDAN: Right, HUMIRA is basically a rounding error now compared to where the immunology franchise is headed. Immunology overall did $8.8 billion, up nearly 15%.

ALEX: Let's talk strategy, because the big headline this quarter was the announced acquisition of Apogee Therapeutics. This adds assets in dermatology, respiratory, and other inflammatory diseases — basically deepening that immunology pipeline for the 2030s and beyond.

JORDAN: It's a dilutive deal in the near term — CFO Scott Reents said it's adding about 14 cents of dilution to full-year EPS guidance, which actually more than offset the underlying business over-performance in the updated guidance. But management framed it as setting up growth well past SKYRIZI and RINVOQ's patent cliffs.

ALEX: Which, by the way, got some clarity on this call too. SKYRIZI's composition patent expires in 2033, but CEO Rob Michael pointed out regulatory data protection runs through 2031, and they don't expect biosimilar filings until the end of the decade. So that runway is longer than some investors might assume.

JORDAN: The other big strategic thread was dermatology — RINVOQ picked up European approvals in vitiligo and alopecia areata, and management now sees combined peak sales for those two indications approaching $2 billion, which is well above what they'd previously guided.

ALEX: There was a great exchange in the Q&A about that too — an analyst pushed on how crowded the vitiligo landscape is getting with other mechanisms coming in. Jeff Stewart's response was basically: these immunology markets keep proving to be way more expansive than people expect once a real systemic treatment shows up, and RINVOQ has the head start plus a decade of safety data behind it.

JORDAN: I also want to flag the SKYRIZI subcutaneous induction story in Crohn's disease — that's got an FDA decision expected this fall. Jeff said they expect a "meaningful acceleration" in SKYRIZI's growth once that's approved, partly because it lets physicians avoid juggling two different reimbursement channels. Management expects that benefit to really show up in early 2027.

ALEX: On the pipeline side, there's a lot cooking beyond immunology too. Parkinson's is shaping up as a real growth story — tavapadone has an FDA decision expected in Q3, and Vyalev is on track for blockbuster status this year. Management still sees the Parkinson's franchise collectively hitting more than $5 billion in peak sales.

JORDAN: Oncology got some att

This episode includes AI-generated content.]]>PHARMA-ABBV-Q2-2026-enFri, 31 Jul 2026 21:51:48 +0000trueBeta FinchMore earnings analysis: https://betafinch.com Groups: PHARMA (https://betafinch.com/groups/PHARMA) ────────── ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. Today we're digging into AbbVie's second quarter 2026 results, and this...https://betafinch.com
Groups: PHARMA (https://betafinch.com/groups/PHARMA)
──────────
ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. Today we're digging into AbbVie's second quarter 2026 results, and this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

JORDAN: And Alex, this was another really strong quarter for AbbVie. Let's just get right into the numbers.

ALEX: Yeah, so adjusted EPS came in at $3.65, which beat guidance by six cents. Total revenue was nearly $17 billion, up 10.2% year over year, and that beat expectations by $300 million. On the back of that, they raised full-year revenue guidance to about $67.6 billion — that's the second raise this year, $600 million total.

JORDAN: What jumps out to me is the breadth of the growth. It's not just one drug carrying the load. SKYRIZI, RINVOQ, and the entire neuroscience portfolio all grew north of 20%. SKYRIZI alone did $5.5 billion in the quarter, up 24%. RINVOQ crossed $2.5 billion, up almost 24%.

ALEX: And that's the story that matters most for AbbVie long-term — how well they've replaced the HUMIRA revenue. Speaking of which, HUMIRA sales were down 36% due to biosimilar competition, but that's expected and honestly just noise at this point given how much SKYRIZI and RINVOQ have scaled up.

JORDAN: Right, HUMIRA is basically a rounding error now compared to where the immunology franchise is headed. Immunology overall did $8.8 billion, up nearly 15%.

ALEX: Let's talk strategy, because the big headline this quarter was the announced acquisition of Apogee Therapeutics. This adds assets in dermatology, respiratory, and other inflammatory diseases — basically deepening that immunology pipeline for the 2030s and beyond.

JORDAN: It's a dilutive deal in the near term — CFO Scott Reents said it's adding about 14 cents of dilution to full-year EPS guidance, which actually more than offset the underlying business over-performance in the updated guidance. But management framed it as setting up growth well past SKYRIZI and RINVOQ's patent cliffs.

ALEX: Which, by the way, got some clarity on this call too. SKYRIZI's composition patent expires in 2033, but CEO Rob Michael pointed out regulatory data protection runs through 2031, and they don't expect biosimilar filings until the end of the decade. So that runway is longer than some investors might assume.

JORDAN: The other big strategic thread was dermatology — RINVOQ picked up European approvals in vitiligo and alopecia areata, and management now sees combined peak sales for those two indications approaching $2 billion, which is well above what they'd previously guided.

ALEX: There was a great exchange in the Q&A about that too — an analyst pushed on how crowded the vitiligo landscape is getting with other mechanisms coming in. Jeff Stewart's response was basically: these immunology markets keep proving to be way more expansive than people expect once a real systemic treatment shows up, and RINVOQ has the head start plus a decade of safety data behind it.

JORDAN: I also want to flag the SKYRIZI subcutaneous induction story in Crohn's disease — that's got an FDA decision expected this fall. Jeff said they expect a "meaningful acceleration" in SKYRIZI's growth once that's approved, partly because it lets physicians avoid juggling two different reimbursement channels. Management expects that benefit to really show up in early 2027.

ALEX: On the pipeline side, there's a lot cooking beyond immunology too. Parkinson's is shaping up as a...]]>392falsefullhttps://www.spreaker.com/episode/bristol-myers-squibb-q2-2026-earnings-analysis--73281019https://betafinch.com
Groups: PHARMA (https://betafinch.com/groups/PHARMA)
──────────
ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown! Today we're digging into Bristol Myers Squibb's second quarter 2026 results, reported Thursday morning. Before we get into it, quick disclaimer: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

JORDAN: And BMY shares were up nearly 2.8% on the news, so investors clearly liked what they heard. Let's get into the numbers.

ALEX: Total revenue for Q2 came in around $13 billion, up 5% year-over-year. The headline story here is what they call the "growth portfolio" — that's their newer drugs — now making up almost 60% of total revenue, growing 14%. Ten different products posted double-digit growth.

JORDAN: That's the story management really wants you to hear — they're successfully transitioning away from legacy products losing patent protection, toward newer assets. And the standouts were impressive: Reblozyl up 29%, Breyanzi up 41%, Camzyos up 59%, and Qvantig — the newer version of their big cancer drug Opdivo — now annualizing over $1 billion.

ALEX: Meanwhile, on the "legacy" side, Eliquis, their blood thinner, actually grew 21% on strong demand, which helped offset declines elsewhere from generic competition, especially as Revlimid keeps facing generics.

JORDAN: Diluted EPS was $2.04 for the quarter, and gross margin held at 71.4%. And because of this strength, management raised full-year guidance for both revenue and adjusted EPS.

ALEX: They also raised their Eliquis growth expectation for the year to 20-25%, and said the overall legacy portfolio decline will be less severe than previously thought — now 4-6% instead of worse.

JORDAN: Balance sheet's solid too — $11.5 billion in cash, $3.4 billion in operating cash flow for the quarter, and they paid down $1.2 billion in debt. So they've got room to keep investing.

ALEX: Now let's talk strategy, because there's a lot happening on the pipeline side. CEO Chris Boerner talked about the company potentially launching more than 10 new medicines by the end of the decade, plus over 30 lifecycle management opportunities.

JORDAN: The near-term catalyst everyone's watching is iberdomide — that's their CELMoD, a new class of oral drug for multiple myeloma. It has an FDA decision date of August 17th, so basically two weeks after this call. If approved, it'd be the first commercialized CELMoD ever.

ALEX: And there's a second one right behind it — mezigdomide — which just got its FDA application accepted with a target decision date of May 2027. Management's pretty bullish these two drugs, along with a third one called golcadomide, could eventually replace older myeloma standards like Revlimid and Pomalyst.

JORDAN: But here's the more nuanced part of the call — two of their biggest pipeline bets just got delayed. Milvexian, a next-generation blood thinner they're developing with Johnson & Johnson... wait, actually it's with partners on the anticoagulant side, competing against their own Eliquis franchise — its atrial fibrillation trial readout got pushed from late 2026 to Q1 2027.

ALEX: And separately, Cobenfy — their schizophrenia drug that they're also testing in Alzheimer's-related psychosis — those readouts are now expected to start in early 2027 instead of this year.

JORDAN: Now, management was pretty insistent both delays are actually good news in disguise. For milvexian, it's an event-driven trial — meaning they need a certain number of stroke and bleeding events to occur before they can read the data. Fewer events happening means the drug might be working better than expected. Chief Medical Officer Cristian Massacesi even pointed out that a competitor's similar trial got stopped early for going the w

This episode includes AI-generated content.]]>PHARMA-BMY-Q2-2026-enFri, 31 Jul 2026 12:04:58 +0000trueBeta FinchMore earnings analysis: https://betafinch.com Groups: PHARMA (https://betafinch.com/groups/PHARMA) ────────── ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown! Today we're digging into Bristol Myers Squibb's second quarter 2026 results,...https://betafinch.com
Groups: PHARMA (https://betafinch.com/groups/PHARMA)
──────────
ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown! Today we're digging into Bristol Myers Squibb's second quarter 2026 results, reported Thursday morning. Before we get into it, quick disclaimer: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

JORDAN: And BMY shares were up nearly 2.8% on the news, so investors clearly liked what they heard. Let's get into the numbers.

ALEX: Total revenue for Q2 came in around $13 billion, up 5% year-over-year. The headline story here is what they call the "growth portfolio" — that's their newer drugs — now making up almost 60% of total revenue, growing 14%. Ten different products posted double-digit growth.

JORDAN: That's the story management really wants you to hear — they're successfully transitioning away from legacy products losing patent protection, toward newer assets. And the standouts were impressive: Reblozyl up 29%, Breyanzi up 41%, Camzyos up 59%, and Qvantig — the newer version of their big cancer drug Opdivo — now annualizing over $1 billion.

ALEX: Meanwhile, on the "legacy" side, Eliquis, their blood thinner, actually grew 21% on strong demand, which helped offset declines elsewhere from generic competition, especially as Revlimid keeps facing generics.

JORDAN: Diluted EPS was $2.04 for the quarter, and gross margin held at 71.4%. And because of this strength, management raised full-year guidance for both revenue and adjusted EPS.

ALEX: They also raised their Eliquis growth expectation for the year to 20-25%, and said the overall legacy portfolio decline will be less severe than previously thought — now 4-6% instead of worse.

JORDAN: Balance sheet's solid too — $11.5 billion in cash, $3.4 billion in operating cash flow for the quarter, and they paid down $1.2 billion in debt. So they've got room to keep investing.

ALEX: Now let's talk strategy, because there's a lot happening on the pipeline side. CEO Chris Boerner talked about the company potentially launching more than 10 new medicines by the end of the decade, plus over 30 lifecycle management opportunities.

JORDAN: The near-term catalyst everyone's watching is iberdomide — that's their CELMoD, a new class of oral drug for multiple myeloma. It has an FDA decision date of August 17th, so basically two weeks after this call. If approved, it'd be the first commercialized CELMoD ever.

ALEX: And there's a second one right behind it — mezigdomide — which just got its FDA application accepted with a target decision date of May 2027. Management's pretty bullish these two drugs, along with a third one called golcadomide, could eventually replace older myeloma standards like Revlimid and Pomalyst.

JORDAN: But here's the more nuanced part of the call — two of their biggest pipeline bets just got delayed. Milvexian, a next-generation blood thinner they're developing with Johnson & Johnson... wait, actually it's with partners on the anticoagulant side, competing against their own Eliquis franchise — its atrial fibrillation trial readout got pushed from late 2026 to Q1 2027.

ALEX: And separately, Cobenfy — their schizophrenia drug that they're also testing in Alzheimer's-related psychosis — those readouts are now expected to start in early 2027 instead of this year.

JORDAN: Now, management was pretty insistent both delays are actually good news in disguise. For milvexian, it's an event-driven trial — meaning they need a certain number of...]]>436falsefullhttps://www.spreaker.com/episode/regeneron-q2-2026-earnings-analysis--73278864https://betafinch.com
Groups: PHARMA (https://betafinch.com/groups/PHARMA)
──────────
ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown! Today we're digging into Regeneron's second quarter 2026 results, and Jordan, this was a big one.

JORDAN: A really strong quarter across the board. But first, the standard note — this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

ALEX: Right. So let's set the scene — before diving into numbers, the call opened with a tribute to longtime board member Art Ryan, who passed away this week. He'd been on Regeneron's board for over two decades, previously ran Prudential. A nice moment of the human side of these calls.

JORDAN: Definitely worth noting. Now, onto the business — total revenue was up 17% year-over-year to $4.3 billion, and non-GAAP EPS grew 11% to $14.29. That's their second straight quarter of double-digit growth on both lines.

ALEX: And the headline here is really the trio of record quarters — Dupixent, EYLEA HD, and Libtayo all hit all-time highs for quarterly sales.

JORDAN: Let's start with Dupixent since it's the big one. Global net sales hit $6 billion, up 38% on a constant currency basis. U.S. sales alone grew 42% to $4.6 billion. That's a drug now serving over 1.5 million patients across nine approved indications.

ALEX: Nine! That's dermatology, asthma, nasal polyps, COPD, eosinophilic esophagitis — it just keeps expanding. And here's something investors should watch: Regeneron fully repaid its $3.1 billion development balance owed to Sanofi. That balance had been suppressing collaboration revenue — about $930 million lower in 2025 and $530 million in the first half of this year.

JORDAN: So starting in Q3, Regeneron gets to keep its full share of collaboration profits. That's a real step-up to the bottom line going forward, not tied to any new sales growth — just an accounting unlock.

ALEX: Exactly. Now let's talk EYLEA HD — this one's on fire. U.S. net sales just under $600 million, up 52% year-over-year. And notably, this was the first quarter EYLEA HD sales actually exceeded the original EYLEA.

JORDAN: That's the conversion story playing out. EYLEA HD now makes up about 60% of the franchise, up from 34% a year ago. Meanwhile legacy EYLEA sales fell 45% as patients and doctors shift over — plus there's now biosimilar competition entering that older product's market.

ALEX: They're also awaiting FDA approval on an EYLEA HD prefilled syringe, which could drive even more adoption. Management sounded confident that could land by year-end.

JORDAN: And rounding out the trio, Libtayo — their oncology drug — hit $489 million globally, up 29%. It's gaining real traction in non-small cell lung cancer, now capturing 20% of new prescriptions, double what it was just last year.

ALEX: Let's talk pipeline for a second, because Regeneron's whole philosophy here is "don't bet on one horse." They've got roughly 50 active clinical programs.

JORDAN: A few near-term catalysts stood out to me. There's cemdisiran, their siRNA therapy for myasthenia gravis, with an FDA decision expected in November — that could be the first siRNA approved for that disease. There's also garetosmab for a rare bone disease called FOP, with an FDA decision expected as soon as August.

ALEX: And on the bigger picture front, they're moving into Phase III trials later this year for both their obesity program — a GLP-GIP combo called olatorepatide — and their anticoagulation program targeting Factor XI, which is a different approach than the traditional blood thinners on the market.

JORDAN: One thing that came up repeatedly in Q&A was the Sanofi relationship. CEO Leonard Schleifer confirmed they're in "productive early discussions" with Sanofi about expanding the collaboratio

This episode includes AI-generated content.]]>PHARMA-REGN-Q2-2026-enFri, 31 Jul 2026 10:16:20 +0000trueBeta FinchMore earnings analysis: https://betafinch.com Groups: PHARMA (https://betafinch.com/groups/PHARMA) ────────── ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown! Today we're digging into Regeneron's second quarter 2026 results, and...https://betafinch.com
Groups: PHARMA (https://betafinch.com/groups/PHARMA)
──────────
ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown! Today we're digging into Regeneron's second quarter 2026 results, and Jordan, this was a big one.

JORDAN: A really strong quarter across the board. But first, the standard note — this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

ALEX: Right. So let's set the scene — before diving into numbers, the call opened with a tribute to longtime board member Art Ryan, who passed away this week. He'd been on Regeneron's board for over two decades, previously ran Prudential. A nice moment of the human side of these calls.

JORDAN: Definitely worth noting. Now, onto the business — total revenue was up 17% year-over-year to $4.3 billion, and non-GAAP EPS grew 11% to $14.29. That's their second straight quarter of double-digit growth on both lines.

ALEX: And the headline here is really the trio of record quarters — Dupixent, EYLEA HD, and Libtayo all hit all-time highs for quarterly sales.

JORDAN: Let's start with Dupixent since it's the big one. Global net sales hit $6 billion, up 38% on a constant currency basis. U.S. sales alone grew 42% to $4.6 billion. That's a drug now serving over 1.5 million patients across nine approved indications.

ALEX: Nine! That's dermatology, asthma, nasal polyps, COPD, eosinophilic esophagitis — it just keeps expanding. And here's something investors should watch: Regeneron fully repaid its $3.1 billion development balance owed to Sanofi. That balance had been suppressing collaboration revenue — about $930 million lower in 2025 and $530 million in the first half of this year.

JORDAN: So starting in Q3, Regeneron gets to keep its full share of collaboration profits. That's a real step-up to the bottom line going forward, not tied to any new sales growth — just an accounting unlock.

ALEX: Exactly. Now let's talk EYLEA HD — this one's on fire. U.S. net sales just under $600 million, up 52% year-over-year. And notably, this was the first quarter EYLEA HD sales actually exceeded the original EYLEA.

JORDAN: That's the conversion story playing out. EYLEA HD now makes up about 60% of the franchise, up from 34% a year ago. Meanwhile legacy EYLEA sales fell 45% as patients and doctors shift over — plus there's now biosimilar competition entering that older product's market.

ALEX: They're also awaiting FDA approval on an EYLEA HD prefilled syringe, which could drive even more adoption. Management sounded confident that could land by year-end.

JORDAN: And rounding out the trio, Libtayo — their oncology drug — hit $489 million globally, up 29%. It's gaining real traction in non-small cell lung cancer, now capturing 20% of new prescriptions, double what it was just last year.

ALEX: Let's talk pipeline for a second, because Regeneron's whole philosophy here is "don't bet on one horse." They've got roughly 50 active clinical programs.

JORDAN: A few near-term catalysts stood out to me. There's cemdisiran, their siRNA therapy for myasthenia gravis, with an FDA decision expected in November — that could be the first siRNA approved for that disease. There's also garetosmab for a rare bone disease called FOP, with an FDA decision expected as soon as August.

ALEX: And on the bigger picture front, they're moving into Phase III trials later this year for both their obesity program — a GLP-GIP combo called olatorepatide — and their anticoagulation program targeting Factor XI,...]]>444falsefullhttps://www.spreaker.com/episode/johnson-johnson-q2-2026-earnings-analysis--73000483https://betafinch.com
Groups: PHARMA (https://betafinch.com/groups/PHARMA), INCOME (https://betafinch.com/groups/INCOME)
──────────
ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. Today we're digging into Johnson & Johnson's second quarter 2026 results, and Jordan, there's a lot to unpack here.

JORDAN: There really is. But first, the fine print — this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

ALEX: Right, so let's get into it. J&J posted $25.3 billion in quarterly sales, up 5.6% operationally. That doesn't sound huge until you realize they absorbed a 460 basis point headwind from STELARA losing patent protection to biosimilars.

JORDAN: Yeah, strip out STELARA and the rest of the business grew double digits. That's the real story. Net earnings came in at $5.5 billion, diluted EPS of $2.27, and on an adjusted basis, EPS was $2.90, up nearly 5% year-over-year. And here's the kicker — they raised full-year guidance. Operational sales growth now expected at 6.5% to 7.1%, and adjusted EPS guidance moved up to $11.50-$11.65.

ALEX: They're also closing in on a milestone — more than $100 billion in annual revenue for the first time in the company's 140-year history.

JORDAN: Which is wild to say out loud. This is a company with 28 different products or platforms each doing over a billion dollars a year. That's not a one-hit-wonder portfolio, that's just breadth everywhere.

ALEX: Let's talk oncology, because that's really where J&J flexed this quarter. DARZALEX, their multiple myeloma drug, did over $4 billion, up almost 18%. But the newer combo therapies are what caught my eye — CARVYKTI up 47.7%, TECVAYLI up 56%, TALVEY up 62.6%.

JORDAN: Those growth rates on top of an already-dominant multiple myeloma franchise are pretty remarkable. And they're not resting — new data showed the TALVEY-DARZALEX combo keeping over 80% of patients progression-free at two years, with overall survival up to 89%. That's the kind of data that extends a franchise's life for years.

ALEX: Then there's the newer launches — ICOTYDE in psoriasis, INLEXZO in bladder cancer, RYBREVANT in lung and now head-and-neck cancer. ICOTYDE in particular is getting a lot of attention. Over 11,000 patients started therapy, 6,000 unique prescribers, and more than half of commercial payers already covering it within 90 days.

JORDAN: What's interesting is how they're positioning it alongside TREMFYA, which by the way had a monster quarter — 71% growth, its first $2 billion quarter. Instead of cannibalizing each other, management's framing ICOTYDE as the go-to first systemic treatment and TREMFYA as the first-choice biologic, especially for patients trending toward psoriatic arthritis. It's a two-pronged attack on the same disease area.

ALEX: Now, MedTech was the softer spot this quarter — only 3.6% growth. Cardiovascular was the drag, mainly Abiomed's heart pump business.

JORDAN: Right, and this is worth unpacking because it wasn't a demand problem. A neutral clinical trial out of the U.K. made physicians more cautious about patient selection for Impella devices, so usage slowed. Management was pretty direct about it — they called it a "behavioral" issue, not structural. They're leaning on their own much larger evidence base, over 40,000 patients studied versus the UK trial's 300, while they wait for their own PROTECT IV trial data, which won't read out until 2027.

ALEX: Meanwhile, three of MedTech's four businesses — surgery, vision, and orthopedics — actually accelerated and beat expectations. So it's really one segment, heart recovery, dragging on an otherwise solid MedTech story.

JORDAN: And there's real excitement building around the robotics pipeline — the OTTAVA surgical robot and MONARCH for urology are both awaiti

This episode includes AI-generated content.]]>PHARMA-JNJ-Q2-2026-enWed, 15 Jul 2026 20:59:42 +0000trueBeta FinchMore earnings analysis: https://betafinch.com Groups: PHARMA (https://betafinch.com/groups/PHARMA), INCOME (https://betafinch.com/groups/INCOME) ────────── ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. Today we're digging into...https://betafinch.com
Groups: PHARMA (https://betafinch.com/groups/PHARMA), INCOME (https://betafinch.com/groups/INCOME)
──────────
ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. Today we're digging into Johnson & Johnson's second quarter 2026 results, and Jordan, there's a lot to unpack here.

JORDAN: There really is. But first, the fine print — this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

ALEX: Right, so let's get into it. J&J posted $25.3 billion in quarterly sales, up 5.6% operationally. That doesn't sound huge until you realize they absorbed a 460 basis point headwind from STELARA losing patent protection to biosimilars.

JORDAN: Yeah, strip out STELARA and the rest of the business grew double digits. That's the real story. Net earnings came in at $5.5 billion, diluted EPS of $2.27, and on an adjusted basis, EPS was $2.90, up nearly 5% year-over-year. And here's the kicker — they raised full-year guidance. Operational sales growth now expected at 6.5% to 7.1%, and adjusted EPS guidance moved up to $11.50-$11.65.

ALEX: They're also closing in on a milestone — more than $100 billion in annual revenue for the first time in the company's 140-year history.

JORDAN: Which is wild to say out loud. This is a company with 28 different products or platforms each doing over a billion dollars a year. That's not a one-hit-wonder portfolio, that's just breadth everywhere.

ALEX: Let's talk oncology, because that's really where J&J flexed this quarter. DARZALEX, their multiple myeloma drug, did over $4 billion, up almost 18%. But the newer combo therapies are what caught my eye — CARVYKTI up 47.7%, TECVAYLI up 56%, TALVEY up 62.6%.

JORDAN: Those growth rates on top of an already-dominant multiple myeloma franchise are pretty remarkable. And they're not resting — new data showed the TALVEY-DARZALEX combo keeping over 80% of patients progression-free at two years, with overall survival up to 89%. That's the kind of data that extends a franchise's life for years.

ALEX: Then there's the newer launches — ICOTYDE in psoriasis, INLEXZO in bladder cancer, RYBREVANT in lung and now head-and-neck cancer. ICOTYDE in particular is getting a lot of attention. Over 11,000 patients started therapy, 6,000 unique prescribers, and more than half of commercial payers already covering it within 90 days.

JORDAN: What's interesting is how they're positioning it alongside TREMFYA, which by the way had a monster quarter — 71% growth, its first $2 billion quarter. Instead of cannibalizing each other, management's framing ICOTYDE as the go-to first systemic treatment and TREMFYA as the first-choice biologic, especially for patients trending toward psoriatic arthritis. It's a two-pronged attack on the same disease area.

ALEX: Now, MedTech was the softer spot this quarter — only 3.6% growth. Cardiovascular was the drag, mainly Abiomed's heart pump business.

JORDAN: Right, and this is worth unpacking because it wasn't a demand problem. A neutral clinical trial out of the U.K. made physicians more cautious about patient selection for Impella devices, so usage slowed. Management was pretty direct about it — they called it a "behavioral" issue, not structural. They're leaning on their own much larger evidence base, over 40,000 patients studied versus the UK trial's 300, while they wait for their own PROTECT IV trial data, which won't read out until 2027.

ALEX: Meanwhile, three of MedTech's four...]]>421falsefullhttps://www.spreaker.com/episode/gilead-sciences-q1-2026-earnings-analysis--71925365https://betafinch.com
Groups: PHARMA (https://betafinch.com/groups/PHARMA)
──────────
**Beta Finch Podcast Script - Gilead Q1 2026 Earnings**

---

**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown! I'm Alex, and I'm joined as always by my co-host Jordan. Today we're diving into Gilead Sciences' first quarter 2026 results - and wow, what a quarter this was for the biotech giant.

Before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

Jordan, Gilead came out swinging with some pretty impressive numbers, didn't they?

**JORDAN:** Absolutely, Alex! Let's start with the headline numbers because they're quite strong. Total product sales hit $6.9 billion, up 5% year-over-year. But here's the kicker - if you exclude their COVID drug Veklury, their base business grew 8% to $6.8 billion. That's solid growth for a company Gilead's size.

**ALEX:** And they're not just talking the talk - they're raising guidance across the board. What stood out to you most about their updated outlook?

**JORDAN:** The HIV business is absolutely on fire. They raised their HIV growth expectations from 6% to 8% for the full year, and get this - their PrEP drug Yes2Go, which prevents HIV, is now expected to hit $1 billion in sales. That would make it a blockbuster drug in just its first full year on the market!

**ALEX:** That's remarkable. Let's break down what's driving this HIV success, because it seems like Gilead is firing on all cylinders here.

**JORDAN:** It really is a multi-pronged success story. Their flagship HIV treatment Biktarvy continues to dominate with over 52% market share in the U.S. - that's a drug pulling in $3.4 billion in the quarter alone. But the real star is Yes2Go, their twice-yearly injectable HIV prevention drug. Sales jumped 72% just from the previous quarter to $166 million.

**ALEX:** And during the Q&A, management seemed pretty confident about Yes2Go's trajectory. What are they seeing that makes them so optimistic?

**JORDAN:** Great question! Johanna Mercier, their commercial chief, mentioned some really encouraging metrics. They now have 95% insurance coverage with 95% of those having zero copay for patients. They're seeing strong uptake from both people switching from other drugs and completely new users. And perhaps most importantly, the "persistency" - meaning people coming back for their second injection - is looking really good.

**ALEX:** Now, Gilead wasn't just focused on HIV this quarter. They made some major acquisition moves. Can you walk us through what they're buying and why?

**JORDAN:** This is where it gets really interesting from a strategic perspective. They closed three major deals: Arcellx for their cancer cell therapy anitocel, they're buying Tubulis for their antibody-drug conjugate technology, and Oral Medicines for autoimmune treatments. The total upfront cost? About $11.5 billion.

**ALEX:** That's a lot of cash! How are investors supposed to think about these deals?

**JORDAN:** Well, it's definitely impacting their near-term earnings - they're actually projecting a loss per share for 2026 because of these upfront costs. But management seemed confident these are strategic investments for the long term. The Arcellx deal brings them anitocel, which they believe could be best-in-class for multiple myeloma. And Tubulis gives them next-generation cancer drug technology that goes beyond their current Trodelvy franchise.

**ALEX:** Speaking of Trodelvy, how's their existing oncology business performing?

**JORDAN:** Trodelvy is growing nicely - up 37% year-over-year to $402 million. They're expecting regulatory decisions this year that could expand its use to first-line breast cancer treatment, which would be a significant ma

This episode includes AI-generated content.]]>PHARMA-GILD-Q1-2026-enFri, 08 May 2026 15:42:14 +0000trueBeta FinchMore earnings analysis: https://betafinch.com Groups: PHARMA (https://betafinch.com/groups/PHARMA) ────────── **Beta Finch Podcast Script - Gilead Q1 2026 Earnings** --- **ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown! I'm Alex,...https://betafinch.com
Groups: PHARMA (https://betafinch.com/groups/PHARMA)
──────────
**Beta Finch Podcast Script - Gilead Q1 2026 Earnings**

---

**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown! I'm Alex, and I'm joined as always by my co-host Jordan. Today we're diving into Gilead Sciences' first quarter 2026 results - and wow, what a quarter this was for the biotech giant.

Before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

Jordan, Gilead came out swinging with some pretty impressive numbers, didn't they?

**JORDAN:** Absolutely, Alex! Let's start with the headline numbers because they're quite strong. Total product sales hit $6.9 billion, up 5% year-over-year. But here's the kicker - if you exclude their COVID drug Veklury, their base business grew 8% to $6.8 billion. That's solid growth for a company Gilead's size.

**ALEX:** And they're not just talking the talk - they're raising guidance across the board. What stood out to you most about their updated outlook?

**JORDAN:** The HIV business is absolutely on fire. They raised their HIV growth expectations from 6% to 8% for the full year, and get this - their PrEP drug Yes2Go, which prevents HIV, is now expected to hit $1 billion in sales. That would make it a blockbuster drug in just its first full year on the market!

**ALEX:** That's remarkable. Let's break down what's driving this HIV success, because it seems like Gilead is firing on all cylinders here.

**JORDAN:** It really is a multi-pronged success story. Their flagship HIV treatment Biktarvy continues to dominate with over 52% market share in the U.S. - that's a drug pulling in $3.4 billion in the quarter alone. But the real star is Yes2Go, their twice-yearly injectable HIV prevention drug. Sales jumped 72% just from the previous quarter to $166 million.

**ALEX:** And during the Q&A, management seemed pretty confident about Yes2Go's trajectory. What are they seeing that makes them so optimistic?

**JORDAN:** Great question! Johanna Mercier, their commercial chief, mentioned some really encouraging metrics. They now have 95% insurance coverage with 95% of those having zero copay for patients. They're seeing strong uptake from both people switching from other drugs and completely new users. And perhaps most importantly, the "persistency" - meaning people coming back for their second injection - is looking really good.

**ALEX:** Now, Gilead wasn't just focused on HIV this quarter. They made some major acquisition moves. Can you walk us through what they're buying and why?

**JORDAN:** This is where it gets really interesting from a strategic perspective. They closed three major deals: Arcellx for their cancer cell therapy anitocel, they're buying Tubulis for their antibody-drug conjugate technology, and Oral Medicines for autoimmune treatments. The total upfront cost? About $11.5 billion.

**ALEX:** That's a lot of cash! How are investors supposed to think about these deals?

**JORDAN:** Well, it's definitely impacting their near-term earnings - they're actually projecting a loss per share for 2026 because of these upfront costs. But management seemed confident these are strategic investments for the long term. The Arcellx deal brings them anitocel, which they believe could be best-in-class for multiple myeloma. And Tubulis gives them next-generation cancer drug technology that goes beyond their current Trodelvy franchise.

**ALEX:**...]]>521falsefullhttps://www.spreaker.com/episode/zoetis-q1-2026-earnings-analysis--71913474https://betafinch.com
Groups: PHARMA (https://betafinch.com/groups/PHARMA)
──────────
# Beta Finch Podcast Script: Zoetis Q1 2026 Earnings

**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we dive deep into quarterly results to help you understand what's really happening in the market. I'm Alex.

**JORDAN:** And I'm Jordan. Before we dig in, this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**ALEX:** Today we're breaking down Zoetis' Q1 2026 earnings - and wow, this was a quarter that really caught investors off guard. Jordan, what's your first take on these numbers?

**JORDAN:** Alex, this was definitely a reality check for the animal health giant. On the surface, flat organic operational revenue growth doesn't look terrible, but when you peel back the layers, there's a lot more going on here. They had about $100 million in sales that shifted from Q4 2025 into Q1 due to fiscal year alignment changes. Without that boost, they would have seen a 5% organic operational decline.

**ALEX:** That's a significant difference. And CEO Kristin Peck was pretty candid about what went wrong, wasn't she?

**JORDAN:** Absolutely. She laid out four key factors that created what she called "a convergence of interconnected dynamics." First, rising prices at veterinary clinics led to lower clinic traffic - pet owners are feeling the pinch. Second, those same pet owners are showing increased price sensitivity, especially for premium products where Zoetis leads. Third, competition intensified across key categories like dermatology and parasiticides, with competitors using aggressive pricing. And fourth - this is crucial - these competitive launches didn't expand the overall market like they have historically.

**ALEX:** That last point seems really important. Historically, when new competitors entered Zoetis markets, the pie got bigger for everyone. But not this time?

**JORDAN:** Exactly. In the past, competition actually helped grow markets - think about how the parasiticide market expanded when new players came in. But this time, with pet owners being more price-conscious and visiting clinics less frequently, new entrants are just taking share from existing players rather than bringing new customers into the market.

**ALEX:** Let's talk specific numbers. How did their key franchises perform?

**JORDAN:** The companion animal business really struggled, particularly in the U.S. where it declined 11%. Their key dermatology franchise - which includes blockbusters like Apoquel and Cytopoint - fell 11% globally to $347 million. The Simparica parasiticide franchise was down 1% to $385 million globally, but that masks an 8% decline in the U.S. And their OA Pain products, Librela and Solensia, dropped 8% combined to $140 million.

**ALEX:** But it wasn't all bad news, right? I noticed livestock performed well.

**JORDAN:** That's the silver lining here. Livestock delivered 12% organic operational growth to $720 million, with broad-based strength across cattle, poultry, and swine. Favorable producer economics and strong protein demand are driving investment in herd health. It really shows the value of Zoetis' diversified portfolio - when companion animal struggles, livestock can pick up some slack.

**ALEX:** What about guidance? I imagine they had to adjust expectations.

**JORDAN:** They definitely had to recalibrate. Full-year revenue growth guidance came down to 2-5% from what was presumably higher expectations, and adjusted net income growth is now expected at 2-6%. CFO Wetteny Joseph noted that while the fiscal year alignment was supposed to provide a 200-250 basis point tailwind, the challenging operating environment more than offset that benefit.

**ALEX:** During the Q&A, there were some pointe

This episode includes AI-generated content.]]>PHARMA-ZTS-Q1-2026-enThu, 07 May 2026 22:07:57 +0000trueBeta FinchMore earnings analysis: https://betafinch.com Groups: PHARMA (https://betafinch.com/groups/PHARMA) ────────── # Beta Finch Podcast Script: Zoetis Q1 2026 Earnings **ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we dive deep...https://betafinch.com
Groups: PHARMA (https://betafinch.com/groups/PHARMA)
──────────
# Beta Finch Podcast Script: Zoetis Q1 2026 Earnings

**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we dive deep into quarterly results to help you understand what's really happening in the market. I'm Alex.

**JORDAN:** And I'm Jordan. Before we dig in, this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**ALEX:** Today we're breaking down Zoetis' Q1 2026 earnings - and wow, this was a quarter that really caught investors off guard. Jordan, what's your first take on these numbers?

**JORDAN:** Alex, this was definitely a reality check for the animal health giant. On the surface, flat organic operational revenue growth doesn't look terrible, but when you peel back the layers, there's a lot more going on here. They had about $100 million in sales that shifted from Q4 2025 into Q1 due to fiscal year alignment changes. Without that boost, they would have seen a 5% organic operational decline.

**ALEX:** That's a significant difference. And CEO Kristin Peck was pretty candid about what went wrong, wasn't she?

**JORDAN:** Absolutely. She laid out four key factors that created what she called "a convergence of interconnected dynamics." First, rising prices at veterinary clinics led to lower clinic traffic - pet owners are feeling the pinch. Second, those same pet owners are showing increased price sensitivity, especially for premium products where Zoetis leads. Third, competition intensified across key categories like dermatology and parasiticides, with competitors using aggressive pricing. And fourth - this is crucial - these competitive launches didn't expand the overall market like they have historically.

**ALEX:** That last point seems really important. Historically, when new competitors entered Zoetis markets, the pie got bigger for everyone. But not this time?

**JORDAN:** Exactly. In the past, competition actually helped grow markets - think about how the parasiticide market expanded when new players came in. But this time, with pet owners being more price-conscious and visiting clinics less frequently, new entrants are just taking share from existing players rather than bringing new customers into the market.

**ALEX:** Let's talk specific numbers. How did their key franchises perform?

**JORDAN:** The companion animal business really struggled, particularly in the U.S. where it declined 11%. Their key dermatology franchise - which includes blockbusters like Apoquel and Cytopoint - fell 11% globally to $347 million. The Simparica parasiticide franchise was down 1% to $385 million globally, but that masks an 8% decline in the U.S. And their OA Pain products, Librela and Solensia, dropped 8% combined to $140 million.

**ALEX:** But it wasn't all bad news, right? I noticed livestock performed well.

**JORDAN:** That's the silver lining here. Livestock delivered 12% organic operational growth to $720 million, with broad-based strength across cattle, poultry, and swine. Favorable producer economics and strong protein demand are driving investment in herd health. It really shows the value of Zoetis' diversified portfolio - when companion animal struggles, livestock can pick up some slack.

**ALEX:** What about guidance? I imagine they had to adjust expectations.

**JORDAN:** They definitely had to recalibrate. Full-year revenue growth guidance came down to 2-5% from what was presumably higher expectations, and adjusted net...]]>507falsefullhttps://www.spreaker.com/episode/pfizer-q1-2026-earnings-analysis--71881369
**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we dive deep into the latest corporate results. I'm Alex, and joining me as always is Jordan. Today we're unpacking Pfizer's Q1 2026 earnings call, and folks, there's quite a bit to unpack here.

Before we dive in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN:** Thanks Alex. And what a quarter this was for Pfizer! They really came out swinging with some impressive numbers and some game-changing legal developments. Should we start with the headline figures?

**ALEX:** Absolutely. Pfizer reported Q1 revenues of $14.5 billion, which actually exceeded their own expectations. That's a 2% operational increase overall, but here's the kicker - if you strip out their COVID products, the underlying business grew about 7% operationally. That's solid growth in a challenging environment.

**JORDAN:** And the earnings story is even better. They hit $0.75 in adjusted diluted earnings per share, again beating expectations. What really caught my attention though was their launched and acquired products - these grew 22% operationally to $3.1 billion in the quarter. That's the portfolio transformation strategy Albert Bourla has been talking about really starting to pay off.

**ALEX:** Speaking of transformative developments, we need to talk about the elephant in the room - or should I say, the legal victories in the room. Pfizer had two major legal wins that could reshape their entire growth trajectory post-2028.

**JORDAN:** Right, the Vyndamax patent settlement is huge. This drug, which treats a rare heart condition, was facing generic competition, but now Pfizer has extended exclusivity until mid-2031. We're talking about a $6 billion-plus product here, Alex. CEO Albert Bourla said this "has the potential to change the growth profile of the company significantly post-2028."

**ALEX:** And then there's the Belgian court ruling on their Comirnaty contracts with EU countries. CFO Dave Denton called this "a positive for future EPS and cash flow." These aren't just minor legal technicalities - these are major financial game-changers that give Pfizer much clearer visibility into their cash flows.

**JORDAN:** Which brings us to one of the most interesting parts of the call - Pfizer's new confidence about their post-2028 growth trajectory. Bourla said they now expect a "5-year period of high single-digit revenue CAGR" starting in 2029. That's a pretty bold statement, especially when you consider they're still navigating some significant patent cliff challenges.

**ALEX:** Let's break that down for listeners. CAGR stands for Compound Annual Growth Rate. So Pfizer is essentially saying that starting in 2029, they expect to grow revenues at a high single-digit percentage rate - so probably 7-9% annually - for five straight years. That would be impressive for any pharma company, let alone one coming off the COVID revenue peaks.

**JORDAN:** And the foundation for that confidence seems to be their pipeline and their recent acquisitions. They mentioned having about 20 pivotal study starts planned this year, 8 key data readouts, and 4 regulatory decisions. That's a packed R&D calendar. They're particularly excited about their oncology portfolio, especially after the Seagen acquisition.

**ALEX:** The oncology story is fascinating. They reported 20% year-over-year growth in their Seagen products, and they've got some potentially blockbuster readouts coming. There's Padcev for bladder cancer, which affects over 600,000 patients globally, and their multiple myeloma drug Elrexfio just hit positive Phase III results.

**JORDAN:** Don't forget about the obesity play with their Metsera acquisition.

This episode includes AI-generated content.]]>PHARMA-PFE-Q1-2026-enTue, 05 May 2026 21:55:11 +0000trueBeta Finch# Beta Finch Podcast Script: Pfizer Q1 2026 Earnings **ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we dive deep into the latest corporate results. I'm Alex, and joining me as always is Jordan. Today we're unpacking...
**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we dive deep into the latest corporate results. I'm Alex, and joining me as always is Jordan. Today we're unpacking Pfizer's Q1 2026 earnings call, and folks, there's quite a bit to unpack here.

Before we dive in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN:** Thanks Alex. And what a quarter this was for Pfizer! They really came out swinging with some impressive numbers and some game-changing legal developments. Should we start with the headline figures?

**ALEX:** Absolutely. Pfizer reported Q1 revenues of $14.5 billion, which actually exceeded their own expectations. That's a 2% operational increase overall, but here's the kicker - if you strip out their COVID products, the underlying business grew about 7% operationally. That's solid growth in a challenging environment.

**JORDAN:** And the earnings story is even better. They hit $0.75 in adjusted diluted earnings per share, again beating expectations. What really caught my attention though was their launched and acquired products - these grew 22% operationally to $3.1 billion in the quarter. That's the portfolio transformation strategy Albert Bourla has been talking about really starting to pay off.

**ALEX:** Speaking of transformative developments, we need to talk about the elephant in the room - or should I say, the legal victories in the room. Pfizer had two major legal wins that could reshape their entire growth trajectory post-2028.

**JORDAN:** Right, the Vyndamax patent settlement is huge. This drug, which treats a rare heart condition, was facing generic competition, but now Pfizer has extended exclusivity until mid-2031. We're talking about a $6 billion-plus product here, Alex. CEO Albert Bourla said this "has the potential to change the growth profile of the company significantly post-2028."

**ALEX:** And then there's the Belgian court ruling on their Comirnaty contracts with EU countries. CFO Dave Denton called this "a positive for future EPS and cash flow." These aren't just minor legal technicalities - these are major financial game-changers that give Pfizer much clearer visibility into their cash flows.

**JORDAN:** Which brings us to one of the most interesting parts of the call - Pfizer's new confidence about their post-2028 growth trajectory. Bourla said they now expect a "5-year period of high single-digit revenue CAGR" starting in 2029. That's a pretty bold statement, especially when you consider they're still navigating some significant patent cliff challenges.

**ALEX:** Let's break that down for listeners. CAGR stands for Compound Annual Growth Rate. So Pfizer is essentially saying that starting in 2029, they expect to grow revenues at a high single-digit percentage rate - so probably 7-9% annually - for five straight years. That would be impressive for any pharma company, let alone one coming off the COVID revenue peaks.

**JORDAN:** And the foundation for that confidence seems to be their pipeline and their recent acquisitions. They mentioned having about 20 pivotal study starts planned this year, 8 key data readouts, and 4 regulatory decisions. That's a packed R&D calendar. They're particularly excited about their oncology portfolio, especially after the Seagen acquisition.

**ALEX:** The oncology story is fascinating. They reported 20% year-over-year growth in their Seagen products, and they've got some potentially blockbuster readouts coming. There's Padcev for bladder cancer, which affects over 600,000 patients globally, and their multiple myeloma drug...]]>552falsefullhttps://www.spreaker.com/episode/vertex-pharmaceuticals-q1-2026-earnings-analysis--71873094
ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown where we dive deep into the numbers that move markets. I'm Alex, and I'm joined as always by my co-host Jordan. Today we're breaking down Vertex Pharmaceuticals' Q1 2026 earnings call - and wow, Jordan, this was packed with updates.

JORDAN: Absolutely, Alex. But before we jump in, let me get our mandatory disclaimer out of the way. This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

ALEX: Thanks, Jordan. Now, let's talk Vertex. This biotech giant just delivered some impressive numbers - $2.99 billion in total revenue for Q1, representing 8% growth year-over-year. But what really caught my attention was how they're diversifying beyond their cystic fibrosis cash cow.

JORDAN: Right, and that diversification story is really the headline here. CEO Reshma Kewalramani emphasized that their newer products - KASJEVY and GERNAVICS - drove about 25% of their total revenue growth. That's a company successfully expanding its footprint beyond a single therapeutic area.

ALEX: Let's break down those newer products. KASJEVY, their gene editing therapy, brought in $43 million in Q1 revenue with over 500 patients now having started treatment. Then there's GERNAVICS for pain management at $29 million in revenue. But the real excitement seems to be around their renal pipeline, particularly something called Povitacicept or "Povi."

JORDAN: Oh, the Povi data was genuinely impressive, Alex. They just completed what Kewalramani called their fastest regulatory submission in company history - 27 days from database lock to filing. The Phase III interim results for IgA nephropathy showed a 52% reduction in proteinuria, which is a key marker doctors watch. Kewalramani described the results as "sparkling from top to bottom."

ALEX: And they're not stopping there with renal disease. They're positioning this as potentially their fourth major franchise alongside CF, blood disorders, and pain. The addressable patient population across their renal programs could be in the hundreds of thousands when you add up all the different kidney diseases they're targeting.

JORDAN: What I found interesting in the Q&A was when analyst Jessica Fye asked about renal potentially rivaling their CF business in size. Kewalramani didn't shy away from that comparison. She pointed out that while each kidney disease is rare, they're "common rare diseases" - IgA nephropathy alone affects about 150,000 patients in North America and Europe.

ALEX: The numbers definitely support the growth story. Non-GAAP earnings per share came in at $4.47, up from $4.06 the previous year. They're managing expenses well while investing heavily in these new areas - SG&A expenses were up 30% year-over-year, but that's driven by commercial investments in pain and renal programs.

JORDAN: Speaking of investments, they spent about $344 million buying back shares in Q1, showing they're returning cash to shareholders while still funding growth. They ended the quarter with $13 billion in cash and investments, so they've got plenty of firepower.

ALEX: Now, it wasn't all good news. They had to discontinue their VX-522 program for CF patients who can't benefit from their current modulators. Kewalramani explained they couldn't overcome tolerability issues related to lung inflammation, likely from the delivery mechanism.

JORDAN: That's about 5,000 patients who still can't be helped by Vertex's current CF portfolio. But Kewalramani was adamant they're not giving up on this population. She said their "commitment to CF is absolute and steadfast" and they'll go back to the drawing board on delivery methods.

ALEX: Let's talk guidance. They're sticking with their full-year revenue guidance of $12.95 to $13.10 billion, repre

This episode includes AI-generated content.]]>PHARMA-VRTX-Q1-2026-enTue, 05 May 2026 09:15:46 +0000trueBeta Finch**Beta Finch Podcast Script** ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown where we dive deep into the numbers that move markets. I'm Alex, and I'm joined as always by my co-host Jordan. Today we're breaking down Vertex...
ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown where we dive deep into the numbers that move markets. I'm Alex, and I'm joined as always by my co-host Jordan. Today we're breaking down Vertex Pharmaceuticals' Q1 2026 earnings call - and wow, Jordan, this was packed with updates.

JORDAN: Absolutely, Alex. But before we jump in, let me get our mandatory disclaimer out of the way. This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

ALEX: Thanks, Jordan. Now, let's talk Vertex. This biotech giant just delivered some impressive numbers - $2.99 billion in total revenue for Q1, representing 8% growth year-over-year. But what really caught my attention was how they're diversifying beyond their cystic fibrosis cash cow.

JORDAN: Right, and that diversification story is really the headline here. CEO Reshma Kewalramani emphasized that their newer products - KASJEVY and GERNAVICS - drove about 25% of their total revenue growth. That's a company successfully expanding its footprint beyond a single therapeutic area.

ALEX: Let's break down those newer products. KASJEVY, their gene editing therapy, brought in $43 million in Q1 revenue with over 500 patients now having started treatment. Then there's GERNAVICS for pain management at $29 million in revenue. But the real excitement seems to be around their renal pipeline, particularly something called Povitacicept or "Povi."

JORDAN: Oh, the Povi data was genuinely impressive, Alex. They just completed what Kewalramani called their fastest regulatory submission in company history - 27 days from database lock to filing. The Phase III interim results for IgA nephropathy showed a 52% reduction in proteinuria, which is a key marker doctors watch. Kewalramani described the results as "sparkling from top to bottom."

ALEX: And they're not stopping there with renal disease. They're positioning this as potentially their fourth major franchise alongside CF, blood disorders, and pain. The addressable patient population across their renal programs could be in the hundreds of thousands when you add up all the different kidney diseases they're targeting.

JORDAN: What I found interesting in the Q&A was when analyst Jessica Fye asked about renal potentially rivaling their CF business in size. Kewalramani didn't shy away from that comparison. She pointed out that while each kidney disease is rare, they're "common rare diseases" - IgA nephropathy alone affects about 150,000 patients in North America and Europe.

ALEX: The numbers definitely support the growth story. Non-GAAP earnings per share came in at $4.47, up from $4.06 the previous year. They're managing expenses well while investing heavily in these new areas - SG&A expenses were up 30% year-over-year, but that's driven by commercial investments in pain and renal programs.

JORDAN: Speaking of investments, they spent about $344 million buying back shares in Q1, showing they're returning cash to shareholders while still funding growth. They ended the quarter with $13 billion in cash and investments, so they've got plenty of firepower.

ALEX: Now, it wasn't all good news. They had to discontinue their VX-522 program for CF patients who can't benefit from their current modulators. Kewalramani explained they couldn't overcome tolerability issues related to lung inflammation, likely from the delivery mechanism.

JORDAN: That's about 5,000 patients who still can't be helped by Vertex's current CF portfolio. But Kewalramani was adamant they're not giving up on this population. She said their "commitment to CF is absolute and steadfast" and they'll go back to the drawing board on delivery...]]>520falsefullhttps://www.spreaker.com/episode/merck-q1-2026-earnings-analysis--71798808
**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, and joining me as always is Jordan. Today we're diving into Merck's Q1 2026 results, and wow - there's a lot to unpack here.

**JORDAN:** That's right, Alex. And before we jump in, I need to share our standard disclaimer. This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**ALEX:** Thanks, Jordan. Now, let's talk about the headline numbers. Merck reported revenue of $16.3 billion for Q1, which represents 5% growth year-over-year, or 3% excluding foreign exchange impacts. But here's the kicker - they actually posted a loss of $1.28 per share.

**JORDAN:** Right, and that loss is entirely due to a massive one-time charge. Merck took a $9 billion hit related to their acquisition of Cidara Therapeutics. Without that charge, they would have been profitable. In fact, they raised their full-year guidance, which tells you management feels pretty good about the underlying business.

**ALEX:** Exactly. They bumped up their revenue guidance to between $65.8 billion and $67 billion for the full year, and raised their EPS guidance to $5.04 to $5.16. But Jordan, let's talk about what's really driving this growth - because it's not just KEYTRUDA anymore.

**JORDAN:** That's the big story here, Alex. Yes, KEYTRUDA sales were still strong at $8 billion, up 8%, but what caught my attention was how diversified their growth drivers are becoming. WINREVAIR, their pulmonary arterial hypertension drug, hit $525 million in sales. That's a relatively new product showing real traction.

**ALEX:** And then there's WELIREG, their oral HIF-2-alpha inhibitor, which saw 43% growth to $199 million. Management highlighted they have over 20 new products launching with what they called "blockbuster potential." CEO Rob Davis mentioned a potential commercial opportunity of over $70 billion by the mid-2030s from these new growth drivers alone.

**JORDAN:** Those are big numbers, Alex. But let's talk about some challenges too. GARDASIL sales dropped 22% to $1.1 billion, mainly due to lower demand in China and Japan. And their new RSV prevention drug ENFLONSIA had minimal sales in Q1, though that was expected due to seasonality.

**ALEX:** True, but management seemed confident about the RSV product ramping up in the second half of the year. What really stood out to me from the call was their focus on AI and partnerships. They announced a multi-year deal with Google Cloud for AI capabilities, plus expanded collaborations with Tempus AI and the Mayo Clinic.

**JORDAN:** That's a smart move, especially in drug development where AI could potentially accelerate research timelines. Speaking of their pipeline, they had some interesting updates. The FDA approved their HIV drug IDVYNSO, and they're expecting several priority reviews in the coming months for cancer treatments.

**ALEX:** The pipeline discussion was fascinating. Dr. Dean Li, their research chief, mentioned they have 17 Phase III studies ongoing for their antibody-drug conjugate sac-TMT, with 13 of those in "first mover" indications. That could be huge if those trials are successful.

**JORDAN:** And let's not forget the Terns Pharmaceutical acquisition they're working on. They're paying about $5.8 billion for TERN-701, a chronic myeloid leukemia drug candidate. Management thinks it has "multibillion-dollar commercial potential."

**ALEX:** During the Q&A, analysts were clearly focused on the pipeline readouts coming this year. There was a lot of discussion about their ophthalmology programs and cancer combination therapies. One thing that struck me was how confident management sounded about their diversification strategy.

**JORDAN:** Absolutely. CFO Caroline Litchfield mentioned

This episode includes AI-generated content.]]>PHARMA-MRK-Q1-2026-enThu, 30 Apr 2026 23:22:14 +0000trueBeta Finch# Beta Finch Podcast Script: Merck Q1 2026 Earnings **ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, and joining me as always is Jordan. Today we're diving into Merck's Q1 2026 results, and wow - there's a lot to unpack...
**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, and joining me as always is Jordan. Today we're diving into Merck's Q1 2026 results, and wow - there's a lot to unpack here.

**JORDAN:** That's right, Alex. And before we jump in, I need to share our standard disclaimer. This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**ALEX:** Thanks, Jordan. Now, let's talk about the headline numbers. Merck reported revenue of $16.3 billion for Q1, which represents 5% growth year-over-year, or 3% excluding foreign exchange impacts. But here's the kicker - they actually posted a loss of $1.28 per share.

**JORDAN:** Right, and that loss is entirely due to a massive one-time charge. Merck took a $9 billion hit related to their acquisition of Cidara Therapeutics. Without that charge, they would have been profitable. In fact, they raised their full-year guidance, which tells you management feels pretty good about the underlying business.

**ALEX:** Exactly. They bumped up their revenue guidance to between $65.8 billion and $67 billion for the full year, and raised their EPS guidance to $5.04 to $5.16. But Jordan, let's talk about what's really driving this growth - because it's not just KEYTRUDA anymore.

**JORDAN:** That's the big story here, Alex. Yes, KEYTRUDA sales were still strong at $8 billion, up 8%, but what caught my attention was how diversified their growth drivers are becoming. WINREVAIR, their pulmonary arterial hypertension drug, hit $525 million in sales. That's a relatively new product showing real traction.

**ALEX:** And then there's WELIREG, their oral HIF-2-alpha inhibitor, which saw 43% growth to $199 million. Management highlighted they have over 20 new products launching with what they called "blockbuster potential." CEO Rob Davis mentioned a potential commercial opportunity of over $70 billion by the mid-2030s from these new growth drivers alone.

**JORDAN:** Those are big numbers, Alex. But let's talk about some challenges too. GARDASIL sales dropped 22% to $1.1 billion, mainly due to lower demand in China and Japan. And their new RSV prevention drug ENFLONSIA had minimal sales in Q1, though that was expected due to seasonality.

**ALEX:** True, but management seemed confident about the RSV product ramping up in the second half of the year. What really stood out to me from the call was their focus on AI and partnerships. They announced a multi-year deal with Google Cloud for AI capabilities, plus expanded collaborations with Tempus AI and the Mayo Clinic.

**JORDAN:** That's a smart move, especially in drug development where AI could potentially accelerate research timelines. Speaking of their pipeline, they had some interesting updates. The FDA approved their HIV drug IDVYNSO, and they're expecting several priority reviews in the coming months for cancer treatments.

**ALEX:** The pipeline discussion was fascinating. Dr. Dean Li, their research chief, mentioned they have 17 Phase III studies ongoing for their antibody-drug conjugate sac-TMT, with 13 of those in "first mover" indications. That could be huge if those trials are successful.

**JORDAN:** And let's not forget the Terns Pharmaceutical acquisition they're working on. They're paying about $5.8 billion for TERN-701, a chronic myeloid leukemia drug candidate. Management thinks it has "multibillion-dollar commercial potential."

**ALEX:** During the Q&A, analysts were clearly focused on the pipeline readouts coming this year. There was a lot of discussion about their ophthalmology programs and cancer combination therapies. One thing that struck me...]]>482falsefullhttps://www.spreaker.com/episode/eli-lilly-q1-2026-earnings-analysis--71798805
**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, and I'm joined as always by my co-host Jordan. Today we're diving into Eli Lilly's first quarter 2026 results - and wow, what a quarter this was. Jordan, before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN:** Thanks Alex. And you're absolutely right about this being a wow quarter. Lilly just posted some absolutely staggering numbers. We're talking about 56% revenue growth year-over-year, bringing in what appears to be massive incretin revenues. But what really caught my attention was their guidance raise - they bumped up their full-year revenue expectations by $2 billion to between $82 and $85 billion.

**ALEX:** That's incredible. Let me put that in perspective for our listeners - the midpoint of that guidance represents 28% growth for the full year. For a company of Lilly's size, that's just phenomenal. And the driving force here is clearly their GLP-1 portfolio - Mounjaro and Zepbound combined brought in $12.8 billion in global revenue just in Q1, contributing $6.7 billion of growth compared to last year.

**JORDAN:** What's fascinating is how this growth is playing out globally. We saw really strong international momentum for Mounjaro. In markets like Brazil and Korea, they're claiming around 60% market share. And here's something interesting - they mentioned that generic semaglutide entry in some markets like India actually seems to be stimulating overall market growth rather than hurting Lilly's position.

**ALEX:** That's a great point about the generics. CEO Dave Ricks made a really insightful comment during the Q&A about how this obesity market behaves differently from traditional pharma categories. He said that because so much of the business is out-of-pocket - 75% of ex-US Mounjaro business and a meaningful portion in the US - they see "quite expansionary volume" when they reduce prices. It's almost like the demand curve is more elastic than typical prescription drugs.

**JORDAN:** Exactly. And speaking of new developments, let's talk about Koundeo - their newly approved oral GLP-1. This is huge because it's the first new incretin medicine launched with obesity as the primary indication, not diabetes. They mentioned having over 20,000 patients treated already with about 80% being new to the class entirely.

**ALEX:** The Koundeo launch strategy is really interesting. They're taking a measured approach - they started with digital campaigns, moved to in-person physician promotion, and they're planning full-scale direct-to-consumer TV advertising in Q3. What I found telling was that they already have over 8,000 prescribers, with a third of them never having prescribed an oral GLP-1 before.

**JORDAN:** And the access piece is critical. They've secured commercial access at two of the three largest pharmacy benefit managers, effective mid-May. Plus, the Medicare Bridge program extension through 2027 could be a game-changer - we're talking about $50 monthly copays for seniors. When an analyst asked about Medicare activation, management indicated this will be a gradual build through 2026 and into 2027.

**ALEX:** Let's talk about their pipeline because they were incredibly busy on the R&D front. They announced four acquisitions this quarter - Orna Therapeutics for autoimmune CAR-T therapies, Centessa for sleep disorders, Colonia for cancer treatments, and Ajax for blood cancers. Plus they had positive Phase III data for multiple programs.

**JORDAN:** The retatrutide data particularly caught my eye. This is their triple agonist - GIP, GLP-1, and glucagon. In the TRANSCEND T2D1 trial, patients lost an average of 25 to 37 pounds while also

This episode includes AI-generated content.]]>PHARMA-LLY-Q1-2026-enThu, 30 Apr 2026 23:22:08 +0000trueBeta Finch# Beta Finch Podcast Script - Eli Lilly Q1 2026 Earnings **ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, and I'm joined as always by my co-host Jordan. Today we're diving into Eli Lilly's first quarter 2026 results -...
**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, and I'm joined as always by my co-host Jordan. Today we're diving into Eli Lilly's first quarter 2026 results - and wow, what a quarter this was. Jordan, before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN:** Thanks Alex. And you're absolutely right about this being a wow quarter. Lilly just posted some absolutely staggering numbers. We're talking about 56% revenue growth year-over-year, bringing in what appears to be massive incretin revenues. But what really caught my attention was their guidance raise - they bumped up their full-year revenue expectations by $2 billion to between $82 and $85 billion.

**ALEX:** That's incredible. Let me put that in perspective for our listeners - the midpoint of that guidance represents 28% growth for the full year. For a company of Lilly's size, that's just phenomenal. And the driving force here is clearly their GLP-1 portfolio - Mounjaro and Zepbound combined brought in $12.8 billion in global revenue just in Q1, contributing $6.7 billion of growth compared to last year.

**JORDAN:** What's fascinating is how this growth is playing out globally. We saw really strong international momentum for Mounjaro. In markets like Brazil and Korea, they're claiming around 60% market share. And here's something interesting - they mentioned that generic semaglutide entry in some markets like India actually seems to be stimulating overall market growth rather than hurting Lilly's position.

**ALEX:** That's a great point about the generics. CEO Dave Ricks made a really insightful comment during the Q&A about how this obesity market behaves differently from traditional pharma categories. He said that because so much of the business is out-of-pocket - 75% of ex-US Mounjaro business and a meaningful portion in the US - they see "quite expansionary volume" when they reduce prices. It's almost like the demand curve is more elastic than typical prescription drugs.

**JORDAN:** Exactly. And speaking of new developments, let's talk about Koundeo - their newly approved oral GLP-1. This is huge because it's the first new incretin medicine launched with obesity as the primary indication, not diabetes. They mentioned having over 20,000 patients treated already with about 80% being new to the class entirely.

**ALEX:** The Koundeo launch strategy is really interesting. They're taking a measured approach - they started with digital campaigns, moved to in-person physician promotion, and they're planning full-scale direct-to-consumer TV advertising in Q3. What I found telling was that they already have over 8,000 prescribers, with a third of them never having prescribed an oral GLP-1 before.

**JORDAN:** And the access piece is critical. They've secured commercial access at two of the three largest pharmacy benefit managers, effective mid-May. Plus, the Medicare Bridge program extension through 2027 could be a game-changer - we're talking about $50 monthly copays for seniors. When an analyst asked about Medicare activation, management indicated this will be a gradual build through 2026 and into 2027.

**ALEX:** Let's talk about their pipeline because they were incredibly busy on the R&D front. They announced four acquisitions this quarter - Orna Therapeutics for autoimmune CAR-T therapies, Centessa for sleep disorders, Colonia for cancer treatments, and Ajax for blood cancers. Plus they had positive Phase III data for multiple programs.

**JORDAN:** The retatrutide data particularly caught my eye. This is their triple agonist - GIP,...]]>503falsefullhttps://www.spreaker.com/episode/bristol-myers-squibb-q1-2026-earnings-analysis--71798801
**ALEX**: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, and joining me as always is Jordan. Today we're diving into Bristol-Myers Squibb's first quarter 2026 results, and there's quite a lot to unpack here.

**JORDAN**: Absolutely, Alex. But before we get started, I want to make sure our listeners know that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**ALEX**: Thanks for that, Jordan. Now, let's talk Bristol-Myers Squibb - ticker BMY. This pharmaceutical giant just reported Q1 results, and honestly, they seem to be firing on multiple cylinders right now.

**JORDAN**: The numbers tell a solid story, Alex. Total revenue came in at $11.5 billion, up 1% year-over-year. But here's what's really interesting - their growth portfolio, which includes their newer, more innovative drugs, grew 9% to $6.2 billion. That's nearly half their total revenue now coming from these growth assets.

**ALEX**: That's a massive shift for a company that's been dealing with patent cliffs on older drugs. What stood out to you in terms of specific products driving this growth?

**JORDAN**: Several winners here. Reblozyl grew 15%, Breyanzi - their CAR-T cell therapy - jumped 53%, and Camzyos nearly doubled to $314 million. But the elephant in the room is still Eliquis, their blood thinner, which brought in $4.1 billion and grew 13% despite facing generic competition eventually.

**ALEX**: Let's talk about what CEO Chris Boerner emphasized during the call. He really hammered home three strategic priorities: focusing R&D on life-threatening diseases, executing on their growth portfolio, and maintaining disciplined capital allocation. But Jordan, what caught my attention was all the talk about late 2026 being a make-or-break period for several key programs.

**JORDAN**: Yes, this is crucial, Alex. They have what Boerner called an "increasing cadence of pivotal readouts" coming in late 2026. We're talking about Milvexian for atrial fibrillation and stroke prevention, Cobenfy for Alzheimer's psychosis, and some important cancer drug data. These aren't just incremental updates - these could define the company's growth trajectory for years.

**ALEX**: Let's break down a couple of these. Milvexian is their Factor XI inhibitor, essentially trying to create a blood thinner with less bleeding risk than current options. How big could this be?

**JORDAN**: Potentially massive, Alex. They're testing it against Eliquis - their own blockbuster drug - trying to show it's just as effective but causes less bleeding. Think about it: if you can reduce the main side effect that keeps doctors from prescribing blood thinners, you could expand the treatable patient population significantly. Adam Lenkowsky, their Chief Commercialization Officer, called it having "true blockbuster potential."

**ALEX**: And then there's Cobenfy, which they're testing in Alzheimer's psychosis. This seems like a completely different approach to treating psychiatric symptoms in dementia patients.

**JORDAN**: Right, and this addresses a huge unmet need. Current antipsychotics used in elderly dementia patients carry black box warnings and cause serious side effects like movement disorders and cognitive impairment. Cobenfy works on a completely different mechanism - muscarinic receptors instead of dopamine. If it works, it could be the first approved treatment specifically for Alzheimer's psychosis.

**ALEX**: Now, during the Q&A, there were some really interesting exchanges. One analyst asked about their confidence levels in these trials, and Chief Medical Officer Cristian Massacesi gave pretty detailed responses about trial design and patient selection.

**JORDAN**: What struck me was how specific they we

This episode includes AI-generated content.]]>PHARMA-BMY-Q1-2026-enThu, 30 Apr 2026 23:22:03 +0000trueBeta Finch# Beta Finch Podcast Script: Bristol-Myers Squibb Q1 2026 Earnings **ALEX**: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, and joining me as always is Jordan. Today we're diving into Bristol-Myers Squibb's first quarter 2026...
**ALEX**: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, and joining me as always is Jordan. Today we're diving into Bristol-Myers Squibb's first quarter 2026 results, and there's quite a lot to unpack here.

**JORDAN**: Absolutely, Alex. But before we get started, I want to make sure our listeners know that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**ALEX**: Thanks for that, Jordan. Now, let's talk Bristol-Myers Squibb - ticker BMY. This pharmaceutical giant just reported Q1 results, and honestly, they seem to be firing on multiple cylinders right now.

**JORDAN**: The numbers tell a solid story, Alex. Total revenue came in at $11.5 billion, up 1% year-over-year. But here's what's really interesting - their growth portfolio, which includes their newer, more innovative drugs, grew 9% to $6.2 billion. That's nearly half their total revenue now coming from these growth assets.

**ALEX**: That's a massive shift for a company that's been dealing with patent cliffs on older drugs. What stood out to you in terms of specific products driving this growth?

**JORDAN**: Several winners here. Reblozyl grew 15%, Breyanzi - their CAR-T cell therapy - jumped 53%, and Camzyos nearly doubled to $314 million. But the elephant in the room is still Eliquis, their blood thinner, which brought in $4.1 billion and grew 13% despite facing generic competition eventually.

**ALEX**: Let's talk about what CEO Chris Boerner emphasized during the call. He really hammered home three strategic priorities: focusing R&D on life-threatening diseases, executing on their growth portfolio, and maintaining disciplined capital allocation. But Jordan, what caught my attention was all the talk about late 2026 being a make-or-break period for several key programs.

**JORDAN**: Yes, this is crucial, Alex. They have what Boerner called an "increasing cadence of pivotal readouts" coming in late 2026. We're talking about Milvexian for atrial fibrillation and stroke prevention, Cobenfy for Alzheimer's psychosis, and some important cancer drug data. These aren't just incremental updates - these could define the company's growth trajectory for years.

**ALEX**: Let's break down a couple of these. Milvexian is their Factor XI inhibitor, essentially trying to create a blood thinner with less bleeding risk than current options. How big could this be?

**JORDAN**: Potentially massive, Alex. They're testing it against Eliquis - their own blockbuster drug - trying to show it's just as effective but causes less bleeding. Think about it: if you can reduce the main side effect that keeps doctors from prescribing blood thinners, you could expand the treatable patient population significantly. Adam Lenkowsky, their Chief Commercialization Officer, called it having "true blockbuster potential."

**ALEX**: And then there's Cobenfy, which they're testing in Alzheimer's psychosis. This seems like a completely different approach to treating psychiatric symptoms in dementia patients.

**JORDAN**: Right, and this addresses a huge unmet need. Current antipsychotics used in elderly dementia patients carry black box warnings and cause serious side effects like movement disorders and cognitive impairment. Cobenfy works on a completely different mechanism - muscarinic receptors instead of dopamine. If it works, it could be the first approved treatment specifically for Alzheimer's psychosis.

**ALEX**: Now, during the Q&A, there were some really interesting exchanges. One analyst asked about their confidence levels in these trials, and Chief Medical Officer Cristian...]]>504falsefullhttps://www.spreaker.com/episode/regeneron-q1-2026-earnings-analysis--71752154
**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we dive deep into the numbers that move markets. I'm Alex.

**JORDAN:** And I'm Jordan. Today we're breaking down Regeneron's first quarter 2026 results, and folks, this biotech giant is firing on all cylinders.

**ALEX:** Before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN:** Absolutely. Now Alex, let's talk numbers because Regeneron just posted some impressive results. Revenue jumped 19% to $3.6 billion, and non-GAAP earnings per share grew 15%. Those are solid double-digit growth numbers across the board.

**ALEX:** What really caught my attention is the DUPIXENT story. This drug is becoming an absolute juggernaut - global net sales hit $4.9 billion in the quarter, up 31% on a constant currency basis. Jordan, we're looking at annualized sales approaching $20 billion for this single drug.

**JORDAN:** It's incredible when you put it in perspective. DUPIXENT is now treating over 1.4 million patients worldwide, and they keep expanding into new indications. This quarter alone, they got approval for allergic fungal rhinosinusitis and chronic spontaneous urticaria in younger patients. It's like they're building a franchise within a franchise.

**ALEX:** Speaking of franchises, let's talk about their eye drug portfolio. EYLEA HD had a strong quarter with U.S. sales of $468 million, up 52% year-over-year. But here's the interesting dynamic - while EYLEA HD is growing rapidly, the original EYLEA is declining as expected, down 36%. It's a classic product transition story.

**JORDAN:** And there's still some uncertainty hanging over that transition. They're waiting on FDA approval for the EYLEA HD prefilled syringe, which missed its April deadline. Management expects a decision this quarter, but it shows how regulatory timing can impact even established companies like Regeneron.

**ALEX:** Now, what really excited me during the call was the pipeline discussion. CEO Leonard Schleifer and Chief Scientific Officer George Yancopoulos laid out some compelling near-term catalysts. They've got this complement inhibitor cemdisiran for myasthenia gravis that showed really impressive Phase 3 results.

**JORDAN:** The data on that was striking. Their drug delivered a 2.3-point improvement compared to placebo, which actually outperformed existing treatments that showed 1.6 to 1.9 points in their trials. Plus, it's dosed quarterly versus every two weeks for competitors. That convenience factor could be huge.

**ALEX:** And then there's their obesity play with olatorepatide. This is where Regeneron is trying to differentiate in the crowded GLP-1 space. Their strategy is fascinating - they want to combine this obesity drug with their cholesterol drug Praluent.

**JORDAN:** George Yancopoulos made a compelling pitch on this during the Q&A. He basically said, imagine you have a GLP-1 that works as well as the best ones out there, but also lowers your bad cholesterol by 50% and reduces cardiovascular risk. Why would anyone choose a different GLP-1? It's an interesting value proposition in a competitive market.

**ALEX:** What struck me about that answer is how confident they sounded. Yancopoulos said it would be a "no-brainer" choice for physicians and patients. That's either brilliant positioning or they're setting themselves up for disappointment. Time will tell.

**JORDAN:** One moment that really stood out was when they announced they're giving away their new gene therapy, Otarmeni, for free in the U.S. This treats genetic hearing loss in children, and they got FDA approval just last week.

**ALEX:** That was such an interesting strategic decision. Schleifer said they'r

This episode includes AI-generated content.]]>PHARMA-REGN-Q1-2026-enWed, 29 Apr 2026 21:44:58 +0000trueBeta Finch# Beta Finch Podcast Script: Regeneron Q1 2026 Earnings **ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we dive deep into the numbers that move markets. I'm Alex. **JORDAN:** And I'm Jordan. Today we're breaking down...
**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we dive deep into the numbers that move markets. I'm Alex.

**JORDAN:** And I'm Jordan. Today we're breaking down Regeneron's first quarter 2026 results, and folks, this biotech giant is firing on all cylinders.

**ALEX:** Before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN:** Absolutely. Now Alex, let's talk numbers because Regeneron just posted some impressive results. Revenue jumped 19% to $3.6 billion, and non-GAAP earnings per share grew 15%. Those are solid double-digit growth numbers across the board.

**ALEX:** What really caught my attention is the DUPIXENT story. This drug is becoming an absolute juggernaut - global net sales hit $4.9 billion in the quarter, up 31% on a constant currency basis. Jordan, we're looking at annualized sales approaching $20 billion for this single drug.

**JORDAN:** It's incredible when you put it in perspective. DUPIXENT is now treating over 1.4 million patients worldwide, and they keep expanding into new indications. This quarter alone, they got approval for allergic fungal rhinosinusitis and chronic spontaneous urticaria in younger patients. It's like they're building a franchise within a franchise.

**ALEX:** Speaking of franchises, let's talk about their eye drug portfolio. EYLEA HD had a strong quarter with U.S. sales of $468 million, up 52% year-over-year. But here's the interesting dynamic - while EYLEA HD is growing rapidly, the original EYLEA is declining as expected, down 36%. It's a classic product transition story.

**JORDAN:** And there's still some uncertainty hanging over that transition. They're waiting on FDA approval for the EYLEA HD prefilled syringe, which missed its April deadline. Management expects a decision this quarter, but it shows how regulatory timing can impact even established companies like Regeneron.

**ALEX:** Now, what really excited me during the call was the pipeline discussion. CEO Leonard Schleifer and Chief Scientific Officer George Yancopoulos laid out some compelling near-term catalysts. They've got this complement inhibitor cemdisiran for myasthenia gravis that showed really impressive Phase 3 results.

**JORDAN:** The data on that was striking. Their drug delivered a 2.3-point improvement compared to placebo, which actually outperformed existing treatments that showed 1.6 to 1.9 points in their trials. Plus, it's dosed quarterly versus every two weeks for competitors. That convenience factor could be huge.

**ALEX:** And then there's their obesity play with olatorepatide. This is where Regeneron is trying to differentiate in the crowded GLP-1 space. Their strategy is fascinating - they want to combine this obesity drug with their cholesterol drug Praluent.

**JORDAN:** George Yancopoulos made a compelling pitch on this during the Q&A. He basically said, imagine you have a GLP-1 that works as well as the best ones out there, but also lowers your bad cholesterol by 50% and reduces cardiovascular risk. Why would anyone choose a different GLP-1? It's an interesting value proposition in a competitive market.

**ALEX:** What struck me about that answer is how confident they sounded. Yancopoulos said it would be a "no-brainer" choice for physicians and patients. That's either brilliant positioning or they're setting themselves up for disappointment. Time will tell.

**JORDAN:** One moment that really stood out was when they announced they're giving away their new gene therapy, Otarmeni, for free in the U.S. This treats genetic...]]>487falsefullhttps://www.spreaker.com/episode/abbvie-q1-2026-earnings-analysis--71752153
**ALEX**: Welcome to Beta Finch, your AI-powered earnings breakdown! I'm Alex, and I'm here with my co-host Jordan to dive into AbbVie's first quarter 2026 results.

**JORDAN**: Hey everyone! Before we jump in, we need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**ALEX**: Absolutely. Now Jordan, AbbVie just delivered what I'd call a knockout quarter. They beat expectations across the board and raised guidance - what stood out to you first?

**JORDAN**: The numbers are impressive, Alex. They hit $2.65 in adjusted earnings per share, which was 7 cents above their guidance midpoint. But what really caught my eye was that revenue growth - 12.4% to $15 billion, beating expectations by $300 million. That's some serious momentum.

**ALEX**: And they're not just celebrating - they're doubling down. They raised their full-year EPS guidance by 12 cents to between $14.08 and $14.28. What's driving this confidence?

**JORDAN**: Two words: Skyrizi and immunology. Skyrizi alone pulled in $4.5 billion in sales, up over 29% operationally. CEO Robert Michael specifically called out the "momentum in immunology and neuroscience" with both segments gaining market share in growing markets. This isn't just about riding a wave - they're creating it.

**ALEX**: The Skyrizi story is fascinating because it shows how a well-positioned drug can dominate even in a competitive landscape. Jeff Stewart, their commercial head, mentioned they have "over 4x basically the in-play share" versus their next competitor. How sustainable is that kind of dominance?

**JORDAN**: That's the million-dollar question, Alex. They're facing new competition, including an oral competitor that launched recently. But Stewart seemed pretty confident during the Q&A, pointing to their head-to-head trials across five different mechanisms in psoriasis, superior durability data, and that convenient quarterly dosing. He even suggested the oral competition might expand the market rather than just steal share.

**ALEX**: Speaking of competition, one analyst specifically asked about competitive pressure, and I found Stewart's response really telling. He basically said their audit data shows NBRx - new prescriptions - hitting all-time highs despite having incredibly high market share already. That suggests real physician preference, not just early adoption.

**JORDAN**: Exactly. And they're not just defending Skyrizi - they're expanding it. The subcutaneous induction data for Crohn's disease looked impressive. Dr. Roopal Thakkar highlighted that in treatment-naive patients, 61% achieved endoscopic response and 73% achieved clinical remission. Those are some serious numbers.

**ALEX**: But here's where it gets really interesting - their combination strategy. Tell our listeners about this Skyrizi plus alpha-4 beta-7 antibody data.

**JORDAN**: This is potentially game-changing, Alex. In their platform study, the combination doubled the endoscopic remission rate compared to either drug alone - about 42% of patients at week 24. And remember, this was in severely refractory patients where 82% had failed advanced treatments. Thakkar called it "potentially transformative efficacy."

**ALEX**: The R&D pipeline seems to be the real story here. They're not just maintaining current success - they're building the next generation. What else caught your attention?

**JORDAN**: Their obesity program is heating up. The early data on ABBV-295, their long-acting amylin analog, showed nearly 10% weight loss in just 12 weeks. In a predominantly male, non-obese population, no less. With a 270-hour half-life, they're talking about potential monthly dosing, which could be huge for patient compliance.

**ALEX**: And let's not forget neu

This episode includes AI-generated content.]]>PHARMA-ABBV-Q1-2026-enWed, 29 Apr 2026 21:44:53 +0000trueBeta Finch# Beta Finch Podcast Script: AbbVie Q1 2026 Earnings **ALEX**: Welcome to Beta Finch, your AI-powered earnings breakdown! I'm Alex, and I'm here with my co-host Jordan to dive into AbbVie's first quarter 2026 results. **JORDAN**: Hey everyone!...
**ALEX**: Welcome to Beta Finch, your AI-powered earnings breakdown! I'm Alex, and I'm here with my co-host Jordan to dive into AbbVie's first quarter 2026 results.

**JORDAN**: Hey everyone! Before we jump in, we need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**ALEX**: Absolutely. Now Jordan, AbbVie just delivered what I'd call a knockout quarter. They beat expectations across the board and raised guidance - what stood out to you first?

**JORDAN**: The numbers are impressive, Alex. They hit $2.65 in adjusted earnings per share, which was 7 cents above their guidance midpoint. But what really caught my eye was that revenue growth - 12.4% to $15 billion, beating expectations by $300 million. That's some serious momentum.

**ALEX**: And they're not just celebrating - they're doubling down. They raised their full-year EPS guidance by 12 cents to between $14.08 and $14.28. What's driving this confidence?

**JORDAN**: Two words: Skyrizi and immunology. Skyrizi alone pulled in $4.5 billion in sales, up over 29% operationally. CEO Robert Michael specifically called out the "momentum in immunology and neuroscience" with both segments gaining market share in growing markets. This isn't just about riding a wave - they're creating it.

**ALEX**: The Skyrizi story is fascinating because it shows how a well-positioned drug can dominate even in a competitive landscape. Jeff Stewart, their commercial head, mentioned they have "over 4x basically the in-play share" versus their next competitor. How sustainable is that kind of dominance?

**JORDAN**: That's the million-dollar question, Alex. They're facing new competition, including an oral competitor that launched recently. But Stewart seemed pretty confident during the Q&A, pointing to their head-to-head trials across five different mechanisms in psoriasis, superior durability data, and that convenient quarterly dosing. He even suggested the oral competition might expand the market rather than just steal share.

**ALEX**: Speaking of competition, one analyst specifically asked about competitive pressure, and I found Stewart's response really telling. He basically said their audit data shows NBRx - new prescriptions - hitting all-time highs despite having incredibly high market share already. That suggests real physician preference, not just early adoption.

**JORDAN**: Exactly. And they're not just defending Skyrizi - they're expanding it. The subcutaneous induction data for Crohn's disease looked impressive. Dr. Roopal Thakkar highlighted that in treatment-naive patients, 61% achieved endoscopic response and 73% achieved clinical remission. Those are some serious numbers.

**ALEX**: But here's where it gets really interesting - their combination strategy. Tell our listeners about this Skyrizi plus alpha-4 beta-7 antibody data.

**JORDAN**: This is potentially game-changing, Alex. In their platform study, the combination doubled the endoscopic remission rate compared to either drug alone - about 42% of patients at week 24. And remember, this was in severely refractory patients where 82% had failed advanced treatments. Thakkar called it "potentially transformative efficacy."

**ALEX**: The R&D pipeline seems to be the real story here. They're not just maintaining current success - they're building the next generation. What else caught your attention?

**JORDAN**: Their obesity program is heating up. The early data on ABBV-295, their long-acting amylin analog, showed nearly 10% weight loss in just 12 weeks. In a predominantly male, non-obese population, no less. With a...]]>478falsefullhttps://www.spreaker.com/episode/zoetis-q4-2025-earnings-analysis--70802634
---

ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown where we decode the numbers that move markets. I'm Alex, and I'm here with my co-host Jordan to dive into Zoetis' Q4 2025 earnings call. Jordan, this was quite the earnings report from the animal health giant.

JORDAN: Absolutely, Alex. But before we jump into the numbers, I need to share an important disclaimer. This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

ALEX: Thanks for that, Jordan. Now, let's talk Zoetis. The company reported some solid numbers for 2025 - $9.5 billion in revenue with 6% organic operational growth, and adjusted net income growing 7% organically. They hit the high end of their November guidance range.

JORDAN: That's right, and what I found particularly interesting is how their international markets really carried the load here. International delivered 8% organic operational revenue growth while the U.S. was at 4%. It really shows the value of having that global diversification, especially when you're dealing with some headwinds in your home market.

ALEX: Speaking of headwinds, CEO Kristin Peck was pretty candid about what they're seeing in the U.S. veterinary market. She mentioned economic pressure on Gen Z and millennial pet owners, which has led to declining therapeutic visits. But here's the fascinating part - emergency and urgent care are still showing strength.

JORDAN: That's such an important distinction, Alex. It's not that pet owners love their animals any less or that underlying demand for care is declining. It's more about price sensitivity and tighter household budgets when it comes to routine care. Pet owners are still bringing their dogs in when they're sick, but they're being more selective about wellness visits.

ALEX: Exactly. And Peck mentioned that clinics are starting to react by taking a more measured approach to the overall cost of care. The company is responding with targeted actions - optimizing their channel mix, increasing outreach to veterinarians, and reinforcing their scientific leadership through expanded medical education.

JORDAN: Let's talk about their star performer - the Simparica franchise. This is really impressive stuff. The franchise grew 12% operationally for the year, with Simparica Trio hitting over $1 billion in U.S. sales alone. That makes it their first brand to cross that billion-dollar threshold in the U.S.

ALEX: And globally, Trio maintained its position as the number one selling canine brand. What I found interesting is their omnichannel strategy - they're seeing double-digit contributions from retail and home delivery channels, which is helping them navigate those headwinds in traditional veterinary clinics.

JORDAN: That's smart positioning. They're essentially meeting customers where they want to shop, whether that's at the vet, at retail, or having products delivered to their home. It's all about convenience and compliance for pet owners.

ALEX: Now, let's address the elephant in the room - their OA pain franchise. This declined 3% operationally, with Librela specifically down 6%. This has been a challenge for Zoetis, and there have been some safety concerns raised about these monoclonal antibody treatments.

JORDAN: Right, but Peck seemed confident about their multipronged strategy to turn this around. She mentioned they're seeing stabilizing monthly sales trends and that veterinarian and pet owner satisfaction remains high. Plus, they're introducing new products like Lanivia and Portela to expand their OA pain portfolio.

ALEX: The guidance for 2026 is what really caught my attention, Jordan. They're projecting 3% to 5% organic operational revenue growth and 3% to 6% adjusted net income growth. That's a bit more conservative than what we've see

This episode includes AI-generated content.]]>PHARMA-ZTS-Q4-2025-enSat, 21 Mar 2026 21:42:17 +0000trueBeta Finch**BETA FINCH PODCAST SCRIPT** --- ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown where we decode the numbers that move markets. I'm Alex, and I'm here with my co-host Jordan to dive into Zoetis' Q4 2025 earnings call. Jordan, this...
---

ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown where we decode the numbers that move markets. I'm Alex, and I'm here with my co-host Jordan to dive into Zoetis' Q4 2025 earnings call. Jordan, this was quite the earnings report from the animal health giant.

JORDAN: Absolutely, Alex. But before we jump into the numbers, I need to share an important disclaimer. This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

ALEX: Thanks for that, Jordan. Now, let's talk Zoetis. The company reported some solid numbers for 2025 - $9.5 billion in revenue with 6% organic operational growth, and adjusted net income growing 7% organically. They hit the high end of their November guidance range.

JORDAN: That's right, and what I found particularly interesting is how their international markets really carried the load here. International delivered 8% organic operational revenue growth while the U.S. was at 4%. It really shows the value of having that global diversification, especially when you're dealing with some headwinds in your home market.

ALEX: Speaking of headwinds, CEO Kristin Peck was pretty candid about what they're seeing in the U.S. veterinary market. She mentioned economic pressure on Gen Z and millennial pet owners, which has led to declining therapeutic visits. But here's the fascinating part - emergency and urgent care are still showing strength.

JORDAN: That's such an important distinction, Alex. It's not that pet owners love their animals any less or that underlying demand for care is declining. It's more about price sensitivity and tighter household budgets when it comes to routine care. Pet owners are still bringing their dogs in when they're sick, but they're being more selective about wellness visits.

ALEX: Exactly. And Peck mentioned that clinics are starting to react by taking a more measured approach to the overall cost of care. The company is responding with targeted actions - optimizing their channel mix, increasing outreach to veterinarians, and reinforcing their scientific leadership through expanded medical education.

JORDAN: Let's talk about their star performer - the Simparica franchise. This is really impressive stuff. The franchise grew 12% operationally for the year, with Simparica Trio hitting over $1 billion in U.S. sales alone. That makes it their first brand to cross that billion-dollar threshold in the U.S.

ALEX: And globally, Trio maintained its position as the number one selling canine brand. What I found interesting is their omnichannel strategy - they're seeing double-digit contributions from retail and home delivery channels, which is helping them navigate those headwinds in traditional veterinary clinics.

JORDAN: That's smart positioning. They're essentially meeting customers where they want to shop, whether that's at the vet, at retail, or having products delivered to their home. It's all about convenience and compliance for pet owners.

ALEX: Now, let's address the elephant in the room - their OA pain franchise. This declined 3% operationally, with Librela specifically down 6%. This has been a challenge for Zoetis, and there have been some safety concerns raised about these monoclonal antibody treatments.

JORDAN: Right, but Peck seemed confident about their multipronged strategy to turn this around. She mentioned they're seeing stabilizing monthly sales trends and that veterinarian and pet owner satisfaction remains high. Plus, they're introducing new products like Lanivia and Portela to expand their OA pain portfolio.

ALEX: The guidance for 2026 is what really caught my attention, Jordan. They're...]]>524falsefullhttps://www.spreaker.com/episode/vertex-pharmaceuticals-q4-2025-earnings-analysis--70802632
ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown where we decode the latest quarterly results to help you understand what really matters in the markets. I'm Alex.

JORDAN: And I'm Jordan. Today we're diving into Vertex Pharmaceuticals' Q4 2025 earnings call - and wow, what a story this company is telling about transformation and growth.

ALEX: Before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

JORDAN: Absolutely. Now Alex, Vertex has been known primarily as the cystic fibrosis company for years, but this earnings call really highlighted how they're becoming something much bigger.

ALEX: That's exactly right, Jordan. Let's start with the headline numbers because they're pretty solid. Q4 revenue hit $3.2 billion, up 10% year-over-year, and full-year 2025 revenue reached $12 billion - that's 9% growth. But here's what caught my attention - CEO Reshma Kewalramani kept emphasizing this word "diversification."

JORDAN: Yes! And you can see it in the numbers. While their cystic fibrosis franchise - which includes drugs like TRIKAFTA - still drives the bulk of revenue with 7% growth globally, they're now generating meaningful revenue from completely different disease areas. KASJEVY, their gene therapy for blood disorders, brought in $116 million for the full year. And Gernavix, their non-opioid pain medication, generated $60 million in just eight months since launch.

ALEX: Let's talk about that diversification strategy because it's really the core story here. Duncan McKechnie, their commercial head, painted a picture of a company that's essentially building three new franchises alongside their CF business - in blood disorders, pain management, and now kidney disease.

JORDAN: The kidney disease piece is fascinating, Alex. They have this drug called Povatacept - or "Povi" as they call it - that's being developed for multiple kidney conditions. What's interesting is how confident management sounded about this becoming their "fourth vertical" as they put it. Kewalramani was practically glowing when discussing the clinical data.

ALEX: Right, and there's a reason for that enthusiasm. In their Phase 2 trial for IgA nephropathy - that's a progressive kidney disease - Povatacept showed a 56% reduction in protein in the urine, which is a key measure of kidney function. They've already submitted for FDA approval and expect to complete that submission in the first half of 2026.

JORDAN: But here's what I found most compelling from an investor perspective - the market opportunity. Management estimates that IgA nephropathy affects 330,000 people in the US and Europe alone. And they're not stopping there - they're studying the same drug for other kidney diseases and even expanding into neurological conditions like myasthenia gravis.

ALEX: The "pipeline-in-a-product" concept, as they called it. One drug, multiple indications, multiple revenue streams. It's a smart strategy, especially given how expensive drug development is these days.

JORDAN: Absolutely. Now let's talk about their guidance for 2026 because it tells us a lot about management's confidence level. They're projecting total revenue between $12.95 billion and $13.1 billion - that's 8-9% growth. But here's the kicker: they expect at least $500 million to come from non-CF products. That's basically triple what they generated from those products in 2025.

ALEX: That's aggressive guidance, Jordan. What gives them confidence they can hit those numbers?

JORDAN: Well, for KASJEVY - their gene therapy - they have great visibility because of how the treatment works. Patients go through a months-long process of cell collection and modification before getting infused

This episode includes AI-generated content.]]>PHARMA-VRTX-Q4-2025-enSat, 21 Mar 2026 21:42:12 +0000trueBeta Finch**Beta Finch Podcast Script: Vertex Pharmaceuticals Q4 2025 Earnings** ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown where we decode the latest quarterly results to help you understand what really matters in the markets. I'm Alex....
ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown where we decode the latest quarterly results to help you understand what really matters in the markets. I'm Alex.

JORDAN: And I'm Jordan. Today we're diving into Vertex Pharmaceuticals' Q4 2025 earnings call - and wow, what a story this company is telling about transformation and growth.

ALEX: Before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

JORDAN: Absolutely. Now Alex, Vertex has been known primarily as the cystic fibrosis company for years, but this earnings call really highlighted how they're becoming something much bigger.

ALEX: That's exactly right, Jordan. Let's start with the headline numbers because they're pretty solid. Q4 revenue hit $3.2 billion, up 10% year-over-year, and full-year 2025 revenue reached $12 billion - that's 9% growth. But here's what caught my attention - CEO Reshma Kewalramani kept emphasizing this word "diversification."

JORDAN: Yes! And you can see it in the numbers. While their cystic fibrosis franchise - which includes drugs like TRIKAFTA - still drives the bulk of revenue with 7% growth globally, they're now generating meaningful revenue from completely different disease areas. KASJEVY, their gene therapy for blood disorders, brought in $116 million for the full year. And Gernavix, their non-opioid pain medication, generated $60 million in just eight months since launch.

ALEX: Let's talk about that diversification strategy because it's really the core story here. Duncan McKechnie, their commercial head, painted a picture of a company that's essentially building three new franchises alongside their CF business - in blood disorders, pain management, and now kidney disease.

JORDAN: The kidney disease piece is fascinating, Alex. They have this drug called Povatacept - or "Povi" as they call it - that's being developed for multiple kidney conditions. What's interesting is how confident management sounded about this becoming their "fourth vertical" as they put it. Kewalramani was practically glowing when discussing the clinical data.

ALEX: Right, and there's a reason for that enthusiasm. In their Phase 2 trial for IgA nephropathy - that's a progressive kidney disease - Povatacept showed a 56% reduction in protein in the urine, which is a key measure of kidney function. They've already submitted for FDA approval and expect to complete that submission in the first half of 2026.

JORDAN: But here's what I found most compelling from an investor perspective - the market opportunity. Management estimates that IgA nephropathy affects 330,000 people in the US and Europe alone. And they're not stopping there - they're studying the same drug for other kidney diseases and even expanding into neurological conditions like myasthenia gravis.

ALEX: The "pipeline-in-a-product" concept, as they called it. One drug, multiple indications, multiple revenue streams. It's a smart strategy, especially given how expensive drug development is these days.

JORDAN: Absolutely. Now let's talk about their guidance for 2026 because it tells us a lot about management's confidence level. They're projecting total revenue between $12.95 billion and $13.1 billion - that's 8-9% growth. But here's the kicker: they expect at least $500 million to come from non-CF products. That's basically triple what they generated from those products in 2025.

ALEX: That's aggressive guidance, Jordan. What gives them confidence they can hit those numbers?

JORDAN: Well, for KASJEVY - their gene therapy - they have great...]]>533falsefullhttps://www.spreaker.com/episode/regeneron-q4-2025-earnings-analysis--70802630
---

**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we dive deep into the numbers that matter. I'm Alex, and I'm joined as always by my co-host Jordan. Today we're breaking down Regeneron's Q4 2025 earnings - and folks, this biotech giant just delivered some fascinating insights into their pipeline and future strategy.

Before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN:** Thanks Alex. And what a quarter to analyze! Regeneron reported total revenue of $3.9 billion, up 3% year-over-year, with some really interesting dynamics happening across their portfolio. The headline number might seem modest, but when you dig into the details, there's a lot more going on here.

**ALEX:** Absolutely. Let's start with the standout performer - Dupixent. Jordan, this drug continues to be an absolute monster for Regeneron and their partner Sanofi.

**JORDAN:** It really is remarkable, Alex. Global Dupixent sales hit $4.9 billion in Q4 alone - that's 32% growth year-over-year. And get this - for the full year 2025, Dupixent brought in $17.8 billion globally. CEO Leonard Schleifer mentioned they now have 1.4 million patients on therapy worldwide across 8 approved indications.

**ALEX:** That's incredible scale. And what I found interesting was how Schleifer emphasized that most of those indications are still "significantly underpenetrated" - suggesting there's still room to grow this massive franchise.

**JORDAN:** Exactly. And speaking of growth, let's talk about their eye care franchise. EYLEA HD had a solid quarter with $506 million in U.S. sales, up 66% year-over-year. But the legacy EYLEA product is facing headwinds - it was down 15% sequentially as biosimilar competition looms.

**ALEX:** Right, and management was very transparent about the challenges ahead. They're expecting multiple biosimilar EYLEA products to launch in 2026, which will intensify competitive pressure. But they seem confident that EYLEA HD can hold its own with its differentiated profile.

**JORDAN:** The FDA just approved EYLEA HD for monthly dosing and a new indication, which should help. And they're waiting on approval for a prefilled syringe version that could make it more convenient for doctors to use. Marion McCourt, their commercial head, seemed optimistic about these enhancements.

**ALEX:** Now Jordan, what really caught my attention was the pipeline discussion. CSO George Yancopoulos laid out an incredibly ambitious clinical development plan.

**JORDAN:** Oh absolutely, Alex. They're planning to initiate 18 new Phase III studies targeting enrollment of 35,000 patients. That's a massive investment in late-stage development across multiple therapeutic areas - oncology, complement diseases, anticoagulation, and more.

**ALEX:** And the financial commitment is significant. CFO Christopher Fenimore guided R&D spending to $5.9-6.1 billion in 2026, up substantially from 2025. That's nearly $6 billion just on research and development!

**JORDAN:** Which brings us to one of the most intriguing parts of the call - their obesity strategy. Instead of just trying to compete head-to-head with existing GLP-1 drugs like Ozempic and Mounjaro, they're taking a differentiated approach.

**ALEX:** This was fascinating. Yancopoulos described their plan to combine a GLP-1/GIP drug with their PCSK9 inhibitor Praluent in a single injection. His quote was memorable - he said imagine if someone invented a new GLP-1 that not only delivers weight loss but also lowers bad cholesterol by 50-60%.

**JORDAN:** That's a clever strategy, Alex. Rather than fighting for an extra 1-2% in weight loss like everyone else, they're adding a completely different benefit. Many obese patients also

This episode includes AI-generated content.]]>PHARMA-REGN-Q4-2025-enSat, 21 Mar 2026 21:42:06 +0000trueBeta Finch**BETA FINCH PODCAST SCRIPT** --- **ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we dive deep into the numbers that matter. I'm Alex, and I'm joined as always by my co-host Jordan. Today we're breaking down Regeneron's Q4...
---

**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we dive deep into the numbers that matter. I'm Alex, and I'm joined as always by my co-host Jordan. Today we're breaking down Regeneron's Q4 2025 earnings - and folks, this biotech giant just delivered some fascinating insights into their pipeline and future strategy.

Before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN:** Thanks Alex. And what a quarter to analyze! Regeneron reported total revenue of $3.9 billion, up 3% year-over-year, with some really interesting dynamics happening across their portfolio. The headline number might seem modest, but when you dig into the details, there's a lot more going on here.

**ALEX:** Absolutely. Let's start with the standout performer - Dupixent. Jordan, this drug continues to be an absolute monster for Regeneron and their partner Sanofi.

**JORDAN:** It really is remarkable, Alex. Global Dupixent sales hit $4.9 billion in Q4 alone - that's 32% growth year-over-year. And get this - for the full year 2025, Dupixent brought in $17.8 billion globally. CEO Leonard Schleifer mentioned they now have 1.4 million patients on therapy worldwide across 8 approved indications.

**ALEX:** That's incredible scale. And what I found interesting was how Schleifer emphasized that most of those indications are still "significantly underpenetrated" - suggesting there's still room to grow this massive franchise.

**JORDAN:** Exactly. And speaking of growth, let's talk about their eye care franchise. EYLEA HD had a solid quarter with $506 million in U.S. sales, up 66% year-over-year. But the legacy EYLEA product is facing headwinds - it was down 15% sequentially as biosimilar competition looms.

**ALEX:** Right, and management was very transparent about the challenges ahead. They're expecting multiple biosimilar EYLEA products to launch in 2026, which will intensify competitive pressure. But they seem confident that EYLEA HD can hold its own with its differentiated profile.

**JORDAN:** The FDA just approved EYLEA HD for monthly dosing and a new indication, which should help. And they're waiting on approval for a prefilled syringe version that could make it more convenient for doctors to use. Marion McCourt, their commercial head, seemed optimistic about these enhancements.

**ALEX:** Now Jordan, what really caught my attention was the pipeline discussion. CSO George Yancopoulos laid out an incredibly ambitious clinical development plan.

**JORDAN:** Oh absolutely, Alex. They're planning to initiate 18 new Phase III studies targeting enrollment of 35,000 patients. That's a massive investment in late-stage development across multiple therapeutic areas - oncology, complement diseases, anticoagulation, and more.

**ALEX:** And the financial commitment is significant. CFO Christopher Fenimore guided R&D spending to $5.9-6.1 billion in 2026, up substantially from 2025. That's nearly $6 billion just on research and development!

**JORDAN:** Which brings us to one of the most intriguing parts of the call - their obesity strategy. Instead of just trying to compete head-to-head with existing GLP-1 drugs like Ozempic and Mounjaro, they're taking a differentiated approach.

**ALEX:** This was fascinating. Yancopoulos described their plan to combine a GLP-1/GIP drug with their PCSK9 inhibitor Praluent in a single injection. His quote was memorable - he said imagine if someone invented a new GLP-1 that not only delivers weight loss but also lowers bad cholesterol by 50-60%.

**JORDAN:** That's a...]]>557falsefullhttps://www.spreaker.com/episode/pfizer-q4-2025-earnings-analysis--70802628
---

**ALEX**: Welcome to Beta Finch, your AI-powered earnings breakdown where we cut through the noise to bring you what really matters from the latest quarterly reports. I'm Alex.

**JORDAN**: And I'm Jordan. Before we dive in, I want to make sure our listeners know that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**ALEX**: Thanks Jordan. Today we're breaking down Pfizer's Q4 2025 earnings, and wow - this was a packed call. We've got solid financial performance, major obesity drug developments, and some really interesting strategic moves. Let's start with the numbers, Jordan.

**JORDAN**: The headline numbers tell a story of resilience, Alex. Pfizer posted $62.6 billion in full-year revenue versus $63.6 billion last year - that's a 2% operational decline. But here's the key detail: when you strip out their COVID products, they actually grew operational revenue by 6%.

**ALEX**: That's huge because it shows the underlying business is healthy. What about profitability?

**JORDAN**: Even better news there. Adjusted earnings per share came in at $3.22 versus $3.11 last year, beating expectations. They expanded gross margins to 76%, and their recently launched and acquired products - which is really their growth engine - delivered over $10 billion in revenue with 14% operational growth.

**ALEX**: Now, the elephant in the room with Pfizer has always been their COVID business decline. How bad was that impact in Q4?

**JORDAN**: Pretty significant. COVID products dropped about 40% operationally year-over-year in Q4. But Alex, this is actually old news at this point. What's more interesting is how well they're managing through it. Their non-COVID business grew 9% in the quarter, driven by products like Abrysvo, Eliquis, Prevnar, and the Vyndaqel family.

**ALEX**: Speaking of managing through challenges, they reaffirmed their 2026 guidance today. Walk us through what they're expecting.

**JORDAN**: They're guiding for $59.5 to $62.5 billion in revenue and $2.80 to $3.00 in adjusted EPS for 2026. What's notable is they're expecting COVID revenues to drop to about $5 billion, and they're anticipating $1.5 billion in revenue compression from generic competition. But even with those headwinds, they expect their core business excluding COVID and loss-of-exclusivity products to grow about 4% operationally.

**ALEX**: Now let's talk about the real headline from today's call - their obesity drug data. This feels like a potential game-changer, Jordan.

**JORDAN**: Absolutely, Alex. They announced results from their VESPER-3 study for PF-3944, which is their investigational obesity treatment. And the key differentiator here is that it's designed for monthly dosing instead of weekly like current GLP-1 drugs.

**ALEX**: Monthly dosing - that's a big deal for patient convenience. What kind of weight loss are we talking about?

**JORDAN**: The data showed 10-12% placebo-adjusted weight loss at 28 weeks for their planned phase 3 doses. But here's what's really interesting - their modeling suggests the higher dose they're planning could deliver nearly 16% weight loss. And importantly, they didn't see a weight loss plateau at 28 weeks, suggesting patients could lose even more weight over time.

**ALEX**: How does that stack up against what's already on the market?

**JORDAN**: It's competitive with existing weekly GLP-1s like Ozempic and Wegovy, but the monthly dosing is the real differentiator. During the Q&A, their commercial team emphasized that reducing from four injections per month to just one could be a major advantage for patient compliance and switching existing patients to their therapy.

**ALEX**: What about side effects? That's always a concern with these obesity drugs.

**JORDAN**: The safety prof

This episode includes AI-generated content.]]>PHARMA-PFE-Q4-2025-enSat, 21 Mar 2026 21:42:00 +0000trueBeta Finch**BETA FINCH PODCAST SCRIPT** --- **ALEX**: Welcome to Beta Finch, your AI-powered earnings breakdown where we cut through the noise to bring you what really matters from the latest quarterly reports. I'm Alex. **JORDAN**: And I'm Jordan. Before we...
---

**ALEX**: Welcome to Beta Finch, your AI-powered earnings breakdown where we cut through the noise to bring you what really matters from the latest quarterly reports. I'm Alex.

**JORDAN**: And I'm Jordan. Before we dive in, I want to make sure our listeners know that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**ALEX**: Thanks Jordan. Today we're breaking down Pfizer's Q4 2025 earnings, and wow - this was a packed call. We've got solid financial performance, major obesity drug developments, and some really interesting strategic moves. Let's start with the numbers, Jordan.

**JORDAN**: The headline numbers tell a story of resilience, Alex. Pfizer posted $62.6 billion in full-year revenue versus $63.6 billion last year - that's a 2% operational decline. But here's the key detail: when you strip out their COVID products, they actually grew operational revenue by 6%.

**ALEX**: That's huge because it shows the underlying business is healthy. What about profitability?

**JORDAN**: Even better news there. Adjusted earnings per share came in at $3.22 versus $3.11 last year, beating expectations. They expanded gross margins to 76%, and their recently launched and acquired products - which is really their growth engine - delivered over $10 billion in revenue with 14% operational growth.

**ALEX**: Now, the elephant in the room with Pfizer has always been their COVID business decline. How bad was that impact in Q4?

**JORDAN**: Pretty significant. COVID products dropped about 40% operationally year-over-year in Q4. But Alex, this is actually old news at this point. What's more interesting is how well they're managing through it. Their non-COVID business grew 9% in the quarter, driven by products like Abrysvo, Eliquis, Prevnar, and the Vyndaqel family.

**ALEX**: Speaking of managing through challenges, they reaffirmed their 2026 guidance today. Walk us through what they're expecting.

**JORDAN**: They're guiding for $59.5 to $62.5 billion in revenue and $2.80 to $3.00 in adjusted EPS for 2026. What's notable is they're expecting COVID revenues to drop to about $5 billion, and they're anticipating $1.5 billion in revenue compression from generic competition. But even with those headwinds, they expect their core business excluding COVID and loss-of-exclusivity products to grow about 4% operationally.

**ALEX**: Now let's talk about the real headline from today's call - their obesity drug data. This feels like a potential game-changer, Jordan.

**JORDAN**: Absolutely, Alex. They announced results from their VESPER-3 study for PF-3944, which is their investigational obesity treatment. And the key differentiator here is that it's designed for monthly dosing instead of weekly like current GLP-1 drugs.

**ALEX**: Monthly dosing - that's a big deal for patient convenience. What kind of weight loss are we talking about?

**JORDAN**: The data showed 10-12% placebo-adjusted weight loss at 28 weeks for their planned phase 3 doses. But here's what's really interesting - their modeling suggests the higher dose they're planning could deliver nearly 16% weight loss. And importantly, they didn't see a weight loss plateau at 28 weeks, suggesting patients could lose even more weight over time.

**ALEX**: How does that stack up against what's already on the market?

**JORDAN**: It's competitive with existing weekly GLP-1s like Ozempic and Wegovy, but the monthly dosing is the real differentiator. During the Q&A, their commercial team emphasized that reducing from four injections per month to just one could be a major advantage for patient...]]>555falsefullhttps://www.spreaker.com/episode/merck-q4-2025-earnings-analysis--70802626
---

**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we cut through the noise to bring you what really matters from corporate America's quarterly reports. I'm Alex.

**JORDAN:** And I'm Jordan. Today we're diving into Merck's Q4 2025 earnings - and folks, this one's got some really interesting moving parts.

**ALEX:** Before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN:** Absolutely. Now Alex, let's start with the headline numbers because Merck delivered some solid, if not spectacular, results.

**ALEX:** Right, so Q4 revenue came in at $16.4 billion - that's 5% growth year-over-year, or 4% if you strip out foreign exchange impacts. But what's really interesting here is the story behind these numbers.

**JORDAN:** Exactly. Keytruda, their blockbuster cancer drug, continues to be the workhorse with $8.4 billion in sales, up 5%. But here's what caught my attention - CEO Rob Davis mentioned they now see a path to over $70 billion in potential commercial opportunity by the mid-2030s. That's $20 billion more than just a year ago!

**ALEX:** That's a massive increase in their pipeline projections. And Jordan, this gets to the heart of what investors are really worried about with Merck - what happens when Keytruda loses patent protection?

**JORDAN:** Bingo. The so-called "patent cliff." But here's where it gets interesting - Davis dropped some news about potentially extending Keytruda's protection. They have additional patents that could push the loss of exclusivity from December 2028 out to May or even November 2029.

**ALEX:** That's huge if it holds up. An extra year of Keytruda exclusivity could be worth billions. But let's talk about some of the challenges they're facing. Gardasil, their HPV vaccine, saw sales drop 35% to $1 billion, largely due to lower demand in China and Japan.

**JORDAN:** Yeah, that's a significant headwind. And looking at their 2026 guidance, they're projecting pretty modest growth - just 1% to 3% revenue growth to between $65.5 and $67 billion. That includes dealing with about $2.5 billion in headwinds from generic competition and pricing pressures.

**ALEX:** Speaking of 2026, there's this massive one-time charge of about $9 billion related to their acquisition of Sidera Therapeutics. This deal is all about MK1406, a potentially first-in-class flu prevention drug.

**JORDAN:** This acquisition really stood out to me. Management thinks MK1406 has greater than $5 billion in revenue potential. It's designed as a long-acting antiviral that could prevent influenza in high-risk individuals - basically a once-per-season shot instead of the traditional annual flu vaccine approach.

**ALEX:** The timing is interesting too, given we're in the middle of what seems to be a pretty severe flu season. Dr. Dean Li, their R&D chief, mentioned they've completed enrollment in the Northern Hemisphere for their Phase 3 trial and are now enrolling patients in the Southern Hemisphere.

**JORDAN:** Let's pivot to some of their other growth drivers. Winrevair, their pulmonary arterial hypertension drug, continues to impress with $467 million in global sales. They had over 1,500 new patients start treatment in the U.S. alone this quarter.

**ALEX:** And they just launched Ohtuvayre for COPD after acquiring Verona Pharma. That brought in $178 million in just part of the quarter. These respiratory drugs are clearly becoming a key growth pillar for Merck post-Keytruda.

**JORDAN:** What I found fascinating in the Q&A was the discussion around their HIV programs. They have this two-drug combination that showed non-inferior results to the standard three-drug regimen. Dr. Li was particularly excited abou

This episode includes AI-generated content.]]>PHARMA-MRK-Q4-2025-enSat, 21 Mar 2026 21:41:54 +0000trueBeta Finch**BETA FINCH PODCAST SCRIPT - MERCK Q4 2025 EARNINGS** --- **ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we cut through the noise to bring you what really matters from corporate America's quarterly reports. I'm Alex....
---

**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we cut through the noise to bring you what really matters from corporate America's quarterly reports. I'm Alex.

**JORDAN:** And I'm Jordan. Today we're diving into Merck's Q4 2025 earnings - and folks, this one's got some really interesting moving parts.

**ALEX:** Before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN:** Absolutely. Now Alex, let's start with the headline numbers because Merck delivered some solid, if not spectacular, results.

**ALEX:** Right, so Q4 revenue came in at $16.4 billion - that's 5% growth year-over-year, or 4% if you strip out foreign exchange impacts. But what's really interesting here is the story behind these numbers.

**JORDAN:** Exactly. Keytruda, their blockbuster cancer drug, continues to be the workhorse with $8.4 billion in sales, up 5%. But here's what caught my attention - CEO Rob Davis mentioned they now see a path to over $70 billion in potential commercial opportunity by the mid-2030s. That's $20 billion more than just a year ago!

**ALEX:** That's a massive increase in their pipeline projections. And Jordan, this gets to the heart of what investors are really worried about with Merck - what happens when Keytruda loses patent protection?

**JORDAN:** Bingo. The so-called "patent cliff." But here's where it gets interesting - Davis dropped some news about potentially extending Keytruda's protection. They have additional patents that could push the loss of exclusivity from December 2028 out to May or even November 2029.

**ALEX:** That's huge if it holds up. An extra year of Keytruda exclusivity could be worth billions. But let's talk about some of the challenges they're facing. Gardasil, their HPV vaccine, saw sales drop 35% to $1 billion, largely due to lower demand in China and Japan.

**JORDAN:** Yeah, that's a significant headwind. And looking at their 2026 guidance, they're projecting pretty modest growth - just 1% to 3% revenue growth to between $65.5 and $67 billion. That includes dealing with about $2.5 billion in headwinds from generic competition and pricing pressures.

**ALEX:** Speaking of 2026, there's this massive one-time charge of about $9 billion related to their acquisition of Sidera Therapeutics. This deal is all about MK1406, a potentially first-in-class flu prevention drug.

**JORDAN:** This acquisition really stood out to me. Management thinks MK1406 has greater than $5 billion in revenue potential. It's designed as a long-acting antiviral that could prevent influenza in high-risk individuals - basically a once-per-season shot instead of the traditional annual flu vaccine approach.

**ALEX:** The timing is interesting too, given we're in the middle of what seems to be a pretty severe flu season. Dr. Dean Li, their R&D chief, mentioned they've completed enrollment in the Northern Hemisphere for their Phase 3 trial and are now enrolling patients in the Southern Hemisphere.

**JORDAN:** Let's pivot to some of their other growth drivers. Winrevair, their pulmonary arterial hypertension drug, continues to impress with $467 million in global sales. They had over 1,500 new patients start treatment in the U.S. alone this quarter.

**ALEX:** And they just launched Ohtuvayre for COPD after acquiring Verona Pharma. That brought in $178 million in just part of the quarter. These respiratory drugs are clearly becoming a key growth pillar for Merck post-Keytruda.

**JORDAN:** What I found fascinating in the Q&A was the...]]>489falsefullhttps://www.spreaker.com/episode/eli-lilly-q4-2025-earnings-analysis--70802624
---

**ALEX**: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, and joining me as always is Jordan. Today we're diving into Eli Lilly's blockbuster Q4 2025 results - and folks, when I say blockbuster, I mean it. This pharmaceutical giant just delivered some truly staggering numbers.

But before we jump in, I need to share our standard disclaimer: This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN**: Thanks Alex. And wow, where do we even start with these numbers? Lilly just reported 45% full-year revenue growth - that's not a typo, folks - forty-five percent. We're talking about $65.2 billion in revenue for 2025, with earnings per share jumping 86% to $24.21.

**ALEX**: It's almost surreal when you see numbers like that from a major pharma company. Jordan, what's driving this incredible performance?

**JORDAN**: It all comes down to one word: incretins. These are the diabetes and obesity drugs that have become absolute juggernauts. Their key products - we're talking Mounjaro, Zepbound, and their international rollouts - generated over $13 billion in Q4 revenue alone and grew 91% compared to the same quarter last year.

**ALEX**: Let's break that down for our listeners. Mounjaro is their diabetes drug, Zepbound is the obesity treatment, but they're essentially the same molecule - tirzepatide - just branded differently for different conditions. And the demand has been absolutely explosive.

**JORDAN**: Exactly. What's fascinating is how they've captured market leadership. In the US, Mounjaro now has over 55% of new prescriptions in the diabetes incretin market, while Zepbound commands nearly 70% share in the branded obesity market. But here's what really caught my attention - they're not just winning in the US anymore.

**ALEX**: Right, their international business has been crushing it. CEO David Ricks mentioned they're now the incretin market share leader outside the US as well. That's a huge development because historically, US pharma companies have struggled to replicate their domestic success internationally, especially in obesity treatments.

**JORDAN**: And they're not slowing down. Looking ahead to 2026, management guided to revenue between $80-83 billion. That's another 25% growth at the midpoint. But here's where it gets interesting - they're expecting significant pricing headwinds.

**ALEX**: This is crucial for investors to understand. Lilly is projecting price declines in the low-to-mid teens for 2026. That's a massive headwind, but they believe volume growth will more than offset it.

**JORDAN**: The pricing pressure comes from several factors. First, they struck a deal with the US government to provide obesity medicines to Medicare patients for just $50 per month out-of-pocket starting no later than July 1st. That's huge for patient access but means lower prices for Lilly.

**ALEX**: They're also facing competition from oral versions of these drugs. During the call, they discussed launching their own oral obesity treatment, orforglipron, which they expect to get FDA approval for in Q2 2026.

**JORDAN**: The oral competition point is really interesting. When Novo Nordisk launched oral Wegovy recently, instead of cannibalizing existing injectable sales, it actually expanded the overall market. Lilly's management seems confident this trend will continue - that oral options bring new patients into treatment rather than just switching existing ones.

**ALEX**: Let's talk about their direct-to-consumer business because this is revolutionary for pharma. They've reached 1 million patients on their US direct-to-patient platform. Think about that - patients are buying prescription obesity drugs directly from the manufacturer, often payin

This episode includes AI-generated content.]]>PHARMA-LLY-Q4-2025-enSat, 21 Mar 2026 21:41:48 +0000trueBeta Finch**Beta Finch Podcast Script: Eli Lilly Q4 2025 Earnings** --- **ALEX**: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, and joining me as always is Jordan. Today we're diving into Eli Lilly's blockbuster Q4 2025 results - and...
---

**ALEX**: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, and joining me as always is Jordan. Today we're diving into Eli Lilly's blockbuster Q4 2025 results - and folks, when I say blockbuster, I mean it. This pharmaceutical giant just delivered some truly staggering numbers.

But before we jump in, I need to share our standard disclaimer: This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN**: Thanks Alex. And wow, where do we even start with these numbers? Lilly just reported 45% full-year revenue growth - that's not a typo, folks - forty-five percent. We're talking about $65.2 billion in revenue for 2025, with earnings per share jumping 86% to $24.21.

**ALEX**: It's almost surreal when you see numbers like that from a major pharma company. Jordan, what's driving this incredible performance?

**JORDAN**: It all comes down to one word: incretins. These are the diabetes and obesity drugs that have become absolute juggernauts. Their key products - we're talking Mounjaro, Zepbound, and their international rollouts - generated over $13 billion in Q4 revenue alone and grew 91% compared to the same quarter last year.

**ALEX**: Let's break that down for our listeners. Mounjaro is their diabetes drug, Zepbound is the obesity treatment, but they're essentially the same molecule - tirzepatide - just branded differently for different conditions. And the demand has been absolutely explosive.

**JORDAN**: Exactly. What's fascinating is how they've captured market leadership. In the US, Mounjaro now has over 55% of new prescriptions in the diabetes incretin market, while Zepbound commands nearly 70% share in the branded obesity market. But here's what really caught my attention - they're not just winning in the US anymore.

**ALEX**: Right, their international business has been crushing it. CEO David Ricks mentioned they're now the incretin market share leader outside the US as well. That's a huge development because historically, US pharma companies have struggled to replicate their domestic success internationally, especially in obesity treatments.

**JORDAN**: And they're not slowing down. Looking ahead to 2026, management guided to revenue between $80-83 billion. That's another 25% growth at the midpoint. But here's where it gets interesting - they're expecting significant pricing headwinds.

**ALEX**: This is crucial for investors to understand. Lilly is projecting price declines in the low-to-mid teens for 2026. That's a massive headwind, but they believe volume growth will more than offset it.

**JORDAN**: The pricing pressure comes from several factors. First, they struck a deal with the US government to provide obesity medicines to Medicare patients for just $50 per month out-of-pocket starting no later than July 1st. That's huge for patient access but means lower prices for Lilly.

**ALEX**: They're also facing competition from oral versions of these drugs. During the call, they discussed launching their own oral obesity treatment, orforglipron, which they expect to get FDA approval for in Q2 2026.

**JORDAN**: The oral competition point is really interesting. When Novo Nordisk launched oral Wegovy recently, instead of cannibalizing existing injectable sales, it actually expanded the overall market. Lilly's management seems confident this trend will continue - that oral options bring new patients into treatment rather than just switching existing ones.

**ALEX**: Let's talk about their direct-to-consumer business because this is revolutionary for pharma. They've reached 1 million...]]>524falsefullhttps://www.spreaker.com/episode/johnson-johnson-q4-2025-earnings-analysis--70802623
ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown where we dive deep into the numbers that matter. I'm Alex, and joining me as always is my co-host Jordan. Today we're dissecting Johnson & Johnson's Q4 2025 earnings call, and wow - what a way to cap off the year.

Before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

JORDAN: Thanks Alex, and yeah, JNJ really delivered here. They're calling 2025 a "catapult year" - and the numbers back that up. Let's start with the headline figures because they're impressive across the board.

ALEX: Absolutely. Fourth quarter operational sales growth came in at 7.1%, which is solid, but the full-year picture is even better. They hit $94.2 billion in total revenue for 2025 with 5.3% operational growth. But here's the kicker, Jordan - they're guiding for $100 billion at the midpoint for 2026. That's a massive psychological milestone for any healthcare company.

JORDAN: Right, and what's fascinating is how they're positioning this growth. CEO Joaquin Duato kept emphasizing their "28 billion-dollar products" - that's an incredible diversification of revenue streams. No other healthcare company has that kind of breadth. They're not relying on one or two blockbusters like some of their competitors.

ALEX: Let's break down the two main segments. On the Innovative Medicine side, they posted 5.3% operational growth for the year, crossing $60 billion in pharma sales for the first time. The star performer here continues to be DARZALEX in multiple myeloma - $14 billion in annual sales with 22% growth. That's just staggering for a drug of that size.

JORDAN: And they're not stopping there. The multiple myeloma franchise is becoming a juggernaut. They mentioned being the number one company in that space, with 80% of patients treated with at least one of their four medicines. Plus, CARVICTI, their CAR-T therapy, is showing strong momentum with over 10,000 patients treated across 14 markets.

ALEX: The immunology story is equally compelling. Tremfya hit $5 billion in sales and grew 65% in Q4 - that's not a typo, sixty-five percent! They're confident it'll exceed $10 billion in peak sales, especially as it continues taking share in inflammatory bowel disease where STELARA used to dominate.

JORDAN: Speaking of STELARA, that's the elephant in the room that's actually becoming less relevant. STELARA declined 48.6% due to biosimilar competition, but here's what's remarkable - JNJ grew double digits for the full year excluding STELARA. They've successfully navigated that cliff, which was a major investor concern.

ALEX: Now let's talk MedTech. 5.4% operational growth for the year with some really strong pockets. Cardiovascular was the standout with 15% operational growth, reaching $9 billion. The Abiomed and Shockwave acquisitions are clearly paying dividends here.

JORDAN: What caught my attention was their robotics ambition. They just submitted their Ottava robotic surgery system for FDA approval via a de novo pathway - meaning there's no predicate device to compare it against. That suggests they truly believe they have something differentiated in a space dominated by Intuitive Surgical.

ALEX: The guidance for 2026 is aggressive but achievable based on their pipeline momentum. 5.7% to 6.7% operational sales growth, with that $100 billion midpoint I mentioned. Adjusted EPS growth of 5.5% at the midpoint, which factors in about $500 million in medtech tariffs - significantly higher than 2025.

JORDAN: I want to highlight something CFO Joe Wolk said about margins. They're expecting at least 50 basis points of adjusted operating margin improvement despite those tariff headwinds and increased investment in

This episode includes AI-generated content.]]>PHARMA-JNJ-Q4-2025-enSat, 21 Mar 2026 21:41:43 +0000trueBeta Finch**Beta Finch Podcast Script: Johnson & Johnson Q4 2025** ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown where we dive deep into the numbers that matter. I'm Alex, and joining me as always is my co-host Jordan. Today we're dissecting...
ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown where we dive deep into the numbers that matter. I'm Alex, and joining me as always is my co-host Jordan. Today we're dissecting Johnson & Johnson's Q4 2025 earnings call, and wow - what a way to cap off the year.

Before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

JORDAN: Thanks Alex, and yeah, JNJ really delivered here. They're calling 2025 a "catapult year" - and the numbers back that up. Let's start with the headline figures because they're impressive across the board.

ALEX: Absolutely. Fourth quarter operational sales growth came in at 7.1%, which is solid, but the full-year picture is even better. They hit $94.2 billion in total revenue for 2025 with 5.3% operational growth. But here's the kicker, Jordan - they're guiding for $100 billion at the midpoint for 2026. That's a massive psychological milestone for any healthcare company.

JORDAN: Right, and what's fascinating is how they're positioning this growth. CEO Joaquin Duato kept emphasizing their "28 billion-dollar products" - that's an incredible diversification of revenue streams. No other healthcare company has that kind of breadth. They're not relying on one or two blockbusters like some of their competitors.

ALEX: Let's break down the two main segments. On the Innovative Medicine side, they posted 5.3% operational growth for the year, crossing $60 billion in pharma sales for the first time. The star performer here continues to be DARZALEX in multiple myeloma - $14 billion in annual sales with 22% growth. That's just staggering for a drug of that size.

JORDAN: And they're not stopping there. The multiple myeloma franchise is becoming a juggernaut. They mentioned being the number one company in that space, with 80% of patients treated with at least one of their four medicines. Plus, CARVICTI, their CAR-T therapy, is showing strong momentum with over 10,000 patients treated across 14 markets.

ALEX: The immunology story is equally compelling. Tremfya hit $5 billion in sales and grew 65% in Q4 - that's not a typo, sixty-five percent! They're confident it'll exceed $10 billion in peak sales, especially as it continues taking share in inflammatory bowel disease where STELARA used to dominate.

JORDAN: Speaking of STELARA, that's the elephant in the room that's actually becoming less relevant. STELARA declined 48.6% due to biosimilar competition, but here's what's remarkable - JNJ grew double digits for the full year excluding STELARA. They've successfully navigated that cliff, which was a major investor concern.

ALEX: Now let's talk MedTech. 5.4% operational growth for the year with some really strong pockets. Cardiovascular was the standout with 15% operational growth, reaching $9 billion. The Abiomed and Shockwave acquisitions are clearly paying dividends here.

JORDAN: What caught my attention was their robotics ambition. They just submitted their Ottava robotic surgery system for FDA approval via a de novo pathway - meaning there's no predicate device to compare it against. That suggests they truly believe they have something differentiated in a space dominated by Intuitive Surgical.

ALEX: The guidance for 2026 is aggressive but achievable based on their pipeline momentum. 5.7% to 6.7% operational sales growth, with that $100 billion midpoint I mentioned. Adjusted EPS growth of 5.5% at the midpoint, which factors in about $500 million in medtech tariffs - significantly higher than 2025.

JORDAN: I want to highlight something CFO Joe Wolk said about margins. They're...]]>533falsefullhttps://www.spreaker.com/episode/gilead-sciences-q4-2025-earnings-analysis--70802621
**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we dive deep into the numbers that move markets. I'm Alex, and as always, I'm joined by my co-host Jordan. Today we're unpacking Gilead Sciences' Q4 2025 results - and folks, there's a lot to dig into here.

Before we jump in though, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN:** Thanks Alex. And what a quarter this was for Gilead! The biotech giant just wrapped up what CEO Dan O'Day called "a remarkable year" - and the numbers certainly back that up. They hit $28.9 billion in total product sales for 2025, beating their guidance range and showing some serious momentum heading into 2026.

**ALEX:** Absolutely, Jordan. Let's break down those headline numbers first. Total product sales came in at $7.9 billion for Q4, up 5% year-over-year. But here's what caught my attention - when you strip out their COVID drug Veclury, which has been declining as expected, their base business actually grew 7% in the quarter and 4% for the full year.

**JORDAN:** That's a key distinction, Alex. And speaking of key numbers, their HIV business - which is still their cash cow - delivered $20.8 billion in sales for the year, up 6%. But here's where it gets interesting: they faced an estimated $900 million headwind from Medicare Part D redesign changes. Without that policy impact, their HIV business would have grown 10%.

**ALEX:** That Medicare Part D impact is huge context, Jordan. For listeners who might not be familiar, this was a policy change that affected how drug pricing works for seniors on Medicare. So when Gilead says their underlying HIV business grew 10%, that's actually pretty impressive growth for what's considered a mature market.

**JORDAN:** Exactly. And let's talk about the star of the show - YES2GO. This is their twice-yearly injectable HIV prevention drug that launched in 2025, and it's already showing blockbuster potential. They did $150 million in sales for the year, and here's the kicker - they're guiding for $800 million in 2026.

**ALEX:** That's more than a 5x increase, Jordan. During the Q&A, analysts were really pressing on how realistic that number is. Management seems confident though, citing 90% payer coverage already - including all major insurers - with about 90% of covered patients getting it with zero co-pay.

**JORDAN:** The coverage piece is critical, Alex. Commercial launch is one thing, but getting insurance companies to pay for a premium-priced injectable is another. The fact that they hit their 90% coverage target well ahead of their one-year timeline suggests the value proposition is resonating with payers.

**ALEX:** Let's shift to their pipeline, because this is where things get really interesting for long-term investors. They have four potential product launches coming in 2026, plus five Phase III data readouts across HIV, cancer, and liver disease.

**JORDAN:** Right, and this diversification strategy is really starting to pay off. Their cancer drug Trodelvy grew 6% to $1.4 billion, and they just got positive Phase III data that could expand it from second-line to first-line treatment in triple-negative breast cancer. That's potentially doubling the addressable market.

**ALEX:** And Trodelvy isn't their only oncology play. They're preparing to launch something called Anidocel - a CAR-T therapy for multiple myeloma. The clinical data looks strong with a 96% overall response rate and what they're calling a "best-in-disease" safety profile.

**JORDAN:** The safety piece is huge in CAR-T, Alex. These are powerful but potentially toxic treatments. If they can deliver the efficacy without the severe side effects, that's a real competitive advant

This episode includes AI-generated content.]]>PHARMA-GILD-Q4-2025-enSat, 21 Mar 2026 21:41:38 +0000trueBeta Finch# Beta Finch Podcast Script: Gilead Q4 2025 Earnings **ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we dive deep into the numbers that move markets. I'm Alex, and as always, I'm joined by my co-host Jordan. Today we're...
**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we dive deep into the numbers that move markets. I'm Alex, and as always, I'm joined by my co-host Jordan. Today we're unpacking Gilead Sciences' Q4 2025 results - and folks, there's a lot to dig into here.

Before we jump in though, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN:** Thanks Alex. And what a quarter this was for Gilead! The biotech giant just wrapped up what CEO Dan O'Day called "a remarkable year" - and the numbers certainly back that up. They hit $28.9 billion in total product sales for 2025, beating their guidance range and showing some serious momentum heading into 2026.

**ALEX:** Absolutely, Jordan. Let's break down those headline numbers first. Total product sales came in at $7.9 billion for Q4, up 5% year-over-year. But here's what caught my attention - when you strip out their COVID drug Veclury, which has been declining as expected, their base business actually grew 7% in the quarter and 4% for the full year.

**JORDAN:** That's a key distinction, Alex. And speaking of key numbers, their HIV business - which is still their cash cow - delivered $20.8 billion in sales for the year, up 6%. But here's where it gets interesting: they faced an estimated $900 million headwind from Medicare Part D redesign changes. Without that policy impact, their HIV business would have grown 10%.

**ALEX:** That Medicare Part D impact is huge context, Jordan. For listeners who might not be familiar, this was a policy change that affected how drug pricing works for seniors on Medicare. So when Gilead says their underlying HIV business grew 10%, that's actually pretty impressive growth for what's considered a mature market.

**JORDAN:** Exactly. And let's talk about the star of the show - YES2GO. This is their twice-yearly injectable HIV prevention drug that launched in 2025, and it's already showing blockbuster potential. They did $150 million in sales for the year, and here's the kicker - they're guiding for $800 million in 2026.

**ALEX:** That's more than a 5x increase, Jordan. During the Q&A, analysts were really pressing on how realistic that number is. Management seems confident though, citing 90% payer coverage already - including all major insurers - with about 90% of covered patients getting it with zero co-pay.

**JORDAN:** The coverage piece is critical, Alex. Commercial launch is one thing, but getting insurance companies to pay for a premium-priced injectable is another. The fact that they hit their 90% coverage target well ahead of their one-year timeline suggests the value proposition is resonating with payers.

**ALEX:** Let's shift to their pipeline, because this is where things get really interesting for long-term investors. They have four potential product launches coming in 2026, plus five Phase III data readouts across HIV, cancer, and liver disease.

**JORDAN:** Right, and this diversification strategy is really starting to pay off. Their cancer drug Trodelvy grew 6% to $1.4 billion, and they just got positive Phase III data that could expand it from second-line to first-line treatment in triple-negative breast cancer. That's potentially doubling the addressable market.

**ALEX:** And Trodelvy isn't their only oncology play. They're preparing to launch something called Anidocel - a CAR-T therapy for multiple myeloma. The clinical data looks strong with a 96% overall response rate and what they're calling a "best-in-disease" safety profile.

**JORDAN:** The safety piece is huge in CAR-T, Alex. These are...]]>522falsefullhttps://www.spreaker.com/episode/bristol-myers-squibb-q4-2025-earnings-analysis--70802619
But first, Jordan, I need to get our mandatory disclaimer out of the way. This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN**: Thanks Alex. And speaking of packed earnings calls, Bristol Myers definitely delivered on that front. Let's start with the headline numbers because they tell quite a story about this company's transformation.

**ALEX**: Absolutely. So Q4 revenue came in flat year-over-year at about $12.5 billion, but here's the key detail that investors need to understand - their growth portfolio, which includes all their newer drugs, grew 15% in the quarter and represented nearly 60% of total revenue. That's a massive shift from where this company was just a few years ago.

**JORDAN**: Right, and for the full year, that growth portfolio grew 17%. What's really impressive is that despite losing roughly $4 billion in revenue from legacy products - we're talking about patent cliffs and generic competition - the growth portfolio almost completely offset those declines. That's the kind of pipeline execution that pharma investors dream about.

**ALEX**: Let's talk about some of those growth drivers. Reblozyl, their blood disorder treatment, crossed $2 billion in annual sales. Breyanzi, their CAR-T cell therapy, grew 47% in Q4. And then you have Camzyos for heart disease growing 57%. These aren't just incremental gains - these are blockbuster-level products hitting their stride.

**JORDAN**: And here's what caught my attention from CEO Christopher Boerner's comments - he emphasized they're entering 2026 with "good momentum." But the real story is what's coming in the pipeline. They're expecting six registrational data readouts in the second half of 2026. That's potentially six new revenue streams or major label expansions.

**ALEX**: Jordan, let's break down that pipeline because it spans multiple therapeutic areas. You've got Milvexian for atrial fibrillation and stroke prevention - that's a massive market where they're trying to compete with their own Eliquis. Then there's admilparent for lung fibrosis, and several multiple myeloma treatments. This isn't just one bet - it's a diversified portfolio of shots on goal.

**JORDAN**: Speaking of Eliquis, that was probably the most complex part of the call. The drug is actually expected to grow 10-15% in 2026, which surprised me given it's facing patent cliffs. But management explained they took a strategic pricing reduction that eliminates certain penalty rebates while expanding patient access.

**ALEX**: That's a fascinating strategy. CFO David Elkins explained that the roughly 40% price reduction actually helps them competitively because it removes inflationary penalties that had been building up over years. It's counterintuitive - lower prices leading to higher growth - but it makes sense when you understand the complex rebate structures in pharma.

**JORDAN**: However, they're also guiding for a $1.5 to $2 billion step-down in Eliquis revenue from 2026 to 2027, primarily due to European patent expiries. So investors are looking at one good year before facing those headwinds.

**ALEX**: Let's talk about their cost management because this is where Bristol Myers is really showing discipline. They delivered $1 billion in cost savings in 2025 and expect another billion over 2026-2027. But here's the smart part - they're reinvesting some of those savings into growth initiatives like their partnership with BioNTech on pemiglatinib.

**JORDAN**: That partnership caught

This episode includes AI-generated content.]]>PHARMA-BMY-Q4-2025-enSat, 21 Mar 2026 21:41:33 +0000trueBeta Finch**ALEX**: Welcome to Beta Finch, your AI-powered earnings breakdown where we decode quarterly reports so you don't have to. I'm Alex, and I'm joined as always by my co-host Jordan. Today we're diving into Bristol Myers Squibb's Q4 2025 earnings call -...
But first, Jordan, I need to get our mandatory disclaimer out of the way. This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN**: Thanks Alex. And speaking of packed earnings calls, Bristol Myers definitely delivered on that front. Let's start with the headline numbers because they tell quite a story about this company's transformation.

**ALEX**: Absolutely. So Q4 revenue came in flat year-over-year at about $12.5 billion, but here's the key detail that investors need to understand - their growth portfolio, which includes all their newer drugs, grew 15% in the quarter and represented nearly 60% of total revenue. That's a massive shift from where this company was just a few years ago.

**JORDAN**: Right, and for the full year, that growth portfolio grew 17%. What's really impressive is that despite losing roughly $4 billion in revenue from legacy products - we're talking about patent cliffs and generic competition - the growth portfolio almost completely offset those declines. That's the kind of pipeline execution that pharma investors dream about.

**ALEX**: Let's talk about some of those growth drivers. Reblozyl, their blood disorder treatment, crossed $2 billion in annual sales. Breyanzi, their CAR-T cell therapy, grew 47% in Q4. And then you have Camzyos for heart disease growing 57%. These aren't just incremental gains - these are blockbuster-level products hitting their stride.

**JORDAN**: And here's what caught my attention from CEO Christopher Boerner's comments - he emphasized they're entering 2026 with "good momentum." But the real story is what's coming in the pipeline. They're expecting six registrational data readouts in the second half of 2026. That's potentially six new revenue streams or major label expansions.

**ALEX**: Jordan, let's break down that pipeline because it spans multiple therapeutic areas. You've got Milvexian for atrial fibrillation and stroke prevention - that's a massive market where they're trying to compete with their own Eliquis. Then there's admilparent for lung fibrosis, and several multiple myeloma treatments. This isn't just one bet - it's a diversified portfolio of shots on goal.

**JORDAN**: Speaking of Eliquis, that was probably the most complex part of the call. The drug is actually expected to grow 10-15% in 2026, which surprised me given it's facing patent cliffs. But management explained they took a strategic pricing reduction that eliminates certain penalty rebates while expanding patient access.

**ALEX**: That's a fascinating strategy. CFO David Elkins explained that the roughly 40% price reduction actually helps them competitively because it removes inflationary penalties that had been building up over years. It's counterintuitive - lower prices leading to higher growth - but it makes sense when you understand the complex rebate structures in pharma.

**JORDAN**: However, they're also guiding for a $1.5 to $2 billion step-down in Eliquis revenue from 2026 to 2027, primarily due to European patent expiries. So investors are looking at one good year before facing those headwinds.

**ALEX**: Let's talk about their cost management because this is where Bristol Myers is really showing discipline. They delivered $1 billion in cost savings in 2025 and expect another billion over 2026-2027. But here's the smart part - they're reinvesting some of those savings...]]>508falsefullhttps://www.spreaker.com/episode/abbvie-q4-2025-earnings-analysis--70802617
---

ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown where we digest the latest corporate earnings so you don't have to. I'm Alex.

JORDAN: And I'm Jordan. Today we're diving into AbbVie's fourth quarter 2025 results, and wow, what a story this pharmaceutical giant has to tell.

ALEX: Before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

JORDAN: Absolutely. Now Alex, AbbVie just delivered what CEO Robert Michael called "another excellent year," and the numbers certainly back that up. Let's start with the headline figures.

ALEX: The numbers are pretty impressive, Jordan. AbbVie hit $61.2 billion in adjusted net revenues for the full year - that's a record high and beat their initial guidance by over $2 billion. They're looking at 8.6% sales growth despite facing nearly $16 billion in HUMIRA erosion since it lost exclusivity.

JORDAN: That HUMIRA erosion is the elephant in the room, isn't it? But what's fascinating is how they've more than offset those losses. Their adjusted earnings per share came in at $10 - that's 54 cents above their initial guidance midpoint. It really shows the power of their newer drugs.

ALEX: Exactly, and speaking of those newer drugs, let's talk about the real stars of the show - SKYRIZI and RINVOQ. These two immunology powerhouses are absolutely crushing it.

JORDAN: The numbers are staggering. Combined, SKYRIZI and RINVOQ delivered about $25.9 billion in revenue - that's an $8 billion increase year-over-year. SKYRIZI alone hit $5 billion in the quarter with 31.9% operational growth, while RINVOQ came in at nearly $2.4 billion with 28.6% growth.

ALEX: And here's what caught my attention - they're already exceeding their 2027 long-term guidance by half a billion dollars. For 2026, they're projecting combined sales of over $31 billion for these two drugs. That's remarkable momentum.

JORDAN: What's really interesting is how they're dominating in specific markets. In psoriasis, SKYRIZI has over 45% prescription share in the U.S. biologic market, and their capture rates for new patients are exceeding 55% - that's four times higher than their next closest competitor.

ALEX: The competitive dynamics in IBD are particularly noteworthy. Despite new competition, SKYRIZI maintains a 75% capture rate in frontline IBD treatment, and it's even higher - 80% - specifically in Crohn's disease.

JORDAN: Now let's talk about what's really exciting for the future - their neuroscience portfolio. This segment delivered over $10.7 billion in revenue with nearly $1.8 billion in growth. But the real story here is Vialev, their Parkinson's treatment.

ALEX: Vialev hit $183 million in the quarter - up 33% sequentially - and management is now projecting it'll reach blockbuster status in 2026. That's a billion-dollar drug in its early launch phase. Pretty remarkable.

JORDAN: And they're not stopping there. They see their entire Parkinson's franchise, including Vialev, Duopa, and the upcoming Tavapadon, potentially reaching $5 billion in peak sales. Add their migraine franchise, which they also expect to exceed $5 billion, and you're talking about some serious long-term growth drivers.

ALEX: Let's shift to their pipeline because that's where AbbVie is really investing for the future. They spent nearly $1 billion more on R&D in 2025, fully funding 90 clinical programs. They also invested over $5 billion in business development.

JORDAN: Some of those acquisitions are fascinating - they picked up an in-vivo CAR-T platform, next-generation psychedelics for depression, a long-acting amylin analog for obesity, and even a novel siRNA platform. They're clearly positioning for the next decade of growth.

ALEX: Speaking of p

This episode includes AI-generated content.]]>PHARMA-ABBV-Q4-2025-enSat, 21 Mar 2026 21:41:27 +0000trueBeta Finch**Beta Finch Podcast Script: AbbVie Q4 2025 Earnings** --- ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown where we digest the latest corporate earnings so you don't have to. I'm Alex. JORDAN: And I'm Jordan. Today we're diving into...
---

ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown where we digest the latest corporate earnings so you don't have to. I'm Alex.

JORDAN: And I'm Jordan. Today we're diving into AbbVie's fourth quarter 2025 results, and wow, what a story this pharmaceutical giant has to tell.

ALEX: Before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

JORDAN: Absolutely. Now Alex, AbbVie just delivered what CEO Robert Michael called "another excellent year," and the numbers certainly back that up. Let's start with the headline figures.

ALEX: The numbers are pretty impressive, Jordan. AbbVie hit $61.2 billion in adjusted net revenues for the full year - that's a record high and beat their initial guidance by over $2 billion. They're looking at 8.6% sales growth despite facing nearly $16 billion in HUMIRA erosion since it lost exclusivity.

JORDAN: That HUMIRA erosion is the elephant in the room, isn't it? But what's fascinating is how they've more than offset those losses. Their adjusted earnings per share came in at $10 - that's 54 cents above their initial guidance midpoint. It really shows the power of their newer drugs.

ALEX: Exactly, and speaking of those newer drugs, let's talk about the real stars of the show - SKYRIZI and RINVOQ. These two immunology powerhouses are absolutely crushing it.

JORDAN: The numbers are staggering. Combined, SKYRIZI and RINVOQ delivered about $25.9 billion in revenue - that's an $8 billion increase year-over-year. SKYRIZI alone hit $5 billion in the quarter with 31.9% operational growth, while RINVOQ came in at nearly $2.4 billion with 28.6% growth.

ALEX: And here's what caught my attention - they're already exceeding their 2027 long-term guidance by half a billion dollars. For 2026, they're projecting combined sales of over $31 billion for these two drugs. That's remarkable momentum.

JORDAN: What's really interesting is how they're dominating in specific markets. In psoriasis, SKYRIZI has over 45% prescription share in the U.S. biologic market, and their capture rates for new patients are exceeding 55% - that's four times higher than their next closest competitor.

ALEX: The competitive dynamics in IBD are particularly noteworthy. Despite new competition, SKYRIZI maintains a 75% capture rate in frontline IBD treatment, and it's even higher - 80% - specifically in Crohn's disease.

JORDAN: Now let's talk about what's really exciting for the future - their neuroscience portfolio. This segment delivered over $10.7 billion in revenue with nearly $1.8 billion in growth. But the real story here is Vialev, their Parkinson's treatment.

ALEX: Vialev hit $183 million in the quarter - up 33% sequentially - and management is now projecting it'll reach blockbuster status in 2026. That's a billion-dollar drug in its early launch phase. Pretty remarkable.

JORDAN: And they're not stopping there. They see their entire Parkinson's franchise, including Vialev, Duopa, and the upcoming Tavapadon, potentially reaching $5 billion in peak sales. Add their migraine franchise, which they also expect to exceed $5 billion, and you're talking about some serious long-term growth drivers.

ALEX: Let's shift to their pipeline because that's where AbbVie is really investing for the future. They spent nearly $1 billion more on R&D in 2025, fully funding 90 clinical programs. They also invested over $5 billion in business development.

JORDAN: Some of those acquisitions are fascinating - they picked up an in-vivo CAR-T platform, next-generation...]]>508falsefull